Stockwinners Market Radar for October 23, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
CERS | Hot Stocks20:18 EDT Cathie Wood's ARK Investment buys 193K shares of Cerus today
|
LYFT... | Hot Stocks20:12 EDT Tesla says CEO says expect to roll out ridehailing in TX, probably in CA in 2025 - Says already have ride-hailing options for employees in Bay Area Says building blocks for ride-hailing functionality has been in development for years. Comments taken from Q3 earnings conference call.
|
TSLA | Hot Stocks20:05 EDT Tesla CEO 'confident' Cybercab to reach volume production in 2026 - Says Cybercab event carried thousands of people with no incidents. Says energy storage business running "like wildfire". Says still on track to deliver "affordable models" in first half of 2025. Says aiming for 2M units per year. Says autonomous driving experiencing "significant improvement". Says Version 13 with FSD is "going out soon". Comments taken from Q3 earnings conference call.
|
CTNT | Hot Stocks19:50 EDT Cheetah Net Supply Chain Service Inc trading halted, news pending
|
NUKK | Hot Stocks19:50 EDT Nukkleus Inc trading halted, news pending
|
MNOV | Hot Stocks19:00 EDT MediciNova announces update of Phase 2/3 MN-166 trial at NEALS meeting - MediciNova announced the lead Principal Investigator of this clinical trial, Bjorn Oskarsson, MD, FAAN presented the update of an ongoing Phase 2/3 clinical trial of MN-166 in Amyotrophic Lateral Sclerosis patients at the 2024 Annual NEALS Meeting being held virtually on Oct 21-24, 2024. The presentation entitled "COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Study Design and Trial Update" was given by Dr. Oskarsson during the poster session. Dr. Oskarsson discussed the background of MN-166 (ibudilast), scientific rationale, study objectives, study design, major inclusion criteria and enrollment update as of October 18, 2024. Additionally, he discussed the new NIH funding Expand Access Protocol clinical trial in ALS patients.
|
GRAL | Hot Stocks18:04 EDT Grail presents initial results from study of Galleri multi-cancer detection test - Grail announced early results from the REFLECTION study, which aims to understand the real-world experience of the Galleri multi-cancer early detection - MCED - 1test in routine clinical settings. The Galleri test is recommended for adults with an elevated risk for cancer. In this study, a diverse population of veterans from U.S. Department of Veterans Affairs sites with toxic exposure but with no symptoms suggestive of cancer were included in study enrollment. Initial results showed that among study participants, the veteran cohort had a cancer signal detection rate consistent with other populations that have received the MCED test. Among the 37 participants with a Cancer Signal Detected, 12 cancer diagnoses were confirmed. More than half of the cases were identified at early stages and the most common cancer signal of origin prediction was lung cancer. Additional cancers could be diagnosed during the remainder of the one-year follow-up period.
|
ASTS | Hot Stocks17:50 EDT AST SpaceMobile secures initial contract with Space Development Agency - AST SpaceMobile announced its selection by the Space Development Agency for an Other Transaction agreement to compete for upcoming prototype demonstration projects under the Hybrid Acquisition for proliferated Low-earth Orbit program. The HALO program is a strategic initiative designed to accelerate the development and deployment of advanced space technologies. With this program, the SDA aims to foster competition, drive innovation, and rapidly deliver cutting-edge capabilities to the Department of Defense. "This initial contract validates our commitment to developing innovative solutions for national security space needs," said Chris Ivory, AST SpaceMobile Chief Commercial Officer and Head of its Government Business Unit. "Our space-based cellular broadband technology has the potential to enhance SDA's stated mission at the transport, tracking, and ground layers in a secure and reliable way."
|
PTEN | Hot Stocks17:49 EDT Patterson-UTI sees Q4 CapEx $150M
|
TSLA | Hot Stocks17:48 EDT Tesla sees 20%-30% vehicle sales growth for 2025 - Says with lower cost vehicles and the advent of autonomy, something like 20%-30% growth is "best guess." Comments taken from Q3 earnings conference call.
|
IBM | Hot Stocks17:44 EDT IBM says pause in discretionary spending impacting consulting business - Says winning in the gen AI space in consulting. Expects to be "set up nicely" for 2025.
|
TSLA | Hot Stocks17:37 EDT Tesla CEO Musk sees 2025 vehicle output growth of 20%-30% - Comments taken from Q3 earnings conference call.
|
TER | Hot Stocks17:31 EDT Teradyne up 4% at $129.15 after Q3 earnings beat
|
URI | Hot Stocks17:30 EDT United Rentals down 3% at $809.20 after Q3 earnings miss
|
ORLY | Hot Stocks17:28 EDT O'Reilly Automotive down 3% at $1,162 after Q3 earnings miss, guidance cut
|
IBM | Hot Stocks17:27 EDT IBM sees FY24 run rate savings of $3.5B, up from prior view of $3B - Sees FY24 tax rate in mid-teens.
|
IBM | Hot Stocks17:26 EDT IBM sees low double digit revenue growth in software in Q4
|
IBM | Hot Stocks17:25 EDT IBM says 'well-positioned' to capture growth from generative AI - Says making "solid progress" transitioning portfolio to higher growth, higher margin businesses.
|
TSLA | Hot Stocks17:23 EDT Tesla says Q3 Powerwall deployments saw record high for 2nd consecutive quarter
|
TSLA | Hot Stocks17:22 EDT Tesla says cost of goods sold per vehicle 'at lowest level ever' at $35.1K - Says Cybertruck has become third best-selling EV in Q3 behind Model Y and Model 3. Says Q3 Supercharger Stations grew 20% to 6.7K, Supercharger Connectors up 22% at 62.4K.
|
IBM | Hot Stocks17:18 EDT IBM says recurring revenue base delivering 'strong growth' - Says "continues to gain traction" in enterprise AI. Says "deepening relationships" with key technology partners. Says "pleased" with free cash flow generation of the business. Says has strong liquidity position with about $14B in cash on the balance sheet. Comments taken from Q3 earnings conference call.
|
NOC | Hot Stocks17:17 EDT Northrop Grumman awarded $1.8B Air Force contract - Northrop Grumman has been awarded a $1.8B contract modification to a previously awarded contract for Next Generation Overhead Persistent Infrared Polar Space Vehicles 1 and 2 for Phase 2 scope to complete the effort through satellite build, launch, and transition to operations. The modification brings the total cumulative face value of the contract to $4.16B. Work will be performed at Redondo Beach, California, and is expected to be completed by April 11, 2031. FY24 research and development funds of $102.09M are being obligated at the time of award. Space Systems Command is the contracting activity.
|
MAT | Hot Stocks17:15 EDT Mattel says raising FY24 savings target to $75M from $60M - Says expects growth in Q4. Says meaningful expansion in gross margin fully offset the Barbie movie comparison in its bottom line relative to the prior year. Says priorities this year are to grow profitability, expand gross margin and generate strong cash flow. Says expects to gain market share in the fourth quarter and full year. Says toy industry continued to perform better than first anticipated heading into 2024. Says expects a good holiday season. Says expects to continue share repurchases. Comments and guidance taken from Q3 earnings conference call.
|
BRO | Hot Stocks17:04 EDT Brown & Brown raises quarterly dividend 15% to 15c per share - The dividend is payable on November 13, 2024, to shareholders of record on November 6, 2024.
|
IBM | Hot Stocks17:04 EDT IBM says raising FY24 operating pre-tax margin expansion to about a point - Sees FY24 free cash flow greater than $12B. Says well positioned to deliver an upward inflection in growth in 2025 Comments taken from investor presentation slides.
|
SHEN | Hot Stocks17:03 EDT Shenandoah boosts dividend 11.1% over December 2023 dividend - The Board of Directors of Shenandoah Telecommunications Company or Shentel declared a cash dividend of 10c per share.The dividend will be payable December 2, to shareholders of record as of the close of business on November 5. This dividend is an increase of 1c per share or 11.1% over the December 2023 dividend and will be Shentel's sixty-fifth consecutive year of annual dividends."We are pleased to announce an increase in the annual dividend, demonstrating our confidence in the long-term growth prospects of our Glo Fiber expansion plans." said President and CEO Christopher E. French.
|
PATH OHI | Hot Stocks17:01 EDT UiPath to transform operations for Omega Healthcare - UiPath (PATH) announced that it is transforming operations for Omega Healthcare (OHI), a global player in revenue cycle management, healthcare and clinical enablement services, through AI-powered automation. "We are honoured to be an AI25 Award Winner again this year, following the recognition last year as an inaugural AI10 Award Winner," said Vijayashree Natarajan, SVP & Head of Technology, Omega Healthcare, who accepted the award at FORWARD. "We continue to innovate through our close collaboration with UiPath to harness the full power of automation, AI and generative AI to ultimately deliver significant outcomes for our customers."
|
SDRL RIG | Hot Stocks16:58 EDT Seadrill up 9% at $38.50 on Bloomberg report of potential merger with Transocean - Transocean (RIG) is also up 2% at $4.20 per share.
|
PFE | Hot Stocks16:48 EDT Pfizer: CDC Advisory Committee expands recommendation for use of Prevnar 20 - Pfizer announced that the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practice voted to expand its recommendation for the use of certain pneumococcal vaccines, including Prevnar 20 for all adults aged 50 and older. This recommendation is pending final approval by the director of the CDC and the Department of Health and Human Services. With respect to Prevnar 20, ACIP recommended: Vaccination is recommended for all adults aged greater than or equal to50 years and for adults aged 19-49 years with certain underlying conditions or risk factors who have not received a PCV or whose vaccination history is unknown.
|
TSLA | Hot Stocks16:45 EDT Tesla up 9% afterhours at $232.52 after Q3 earnings beat
|
PXDT | Hot Stocks16:42 EDT Pixie Dust provides update on plan to delist from Nasdaq and deregister from SEC - Pixie Dust resolved to delist its ADRs from NASDAQ and submit an application for deregistration with the SEC. The company has also announced that it has notified NASDAQ of its intention to delist its ADRs voluntarily. The company listed its ADRs on NASDAQ in August 2023. The company has now decided to delist its ADRs due to the substantial cost of maintaining its NASDAQ listing and the ongoing reporting obligations of the United States Securities laws, and considering all other facts and circumstances, the company has decided to divert its financial and human resources toward its business growth. Consequently, the company has also decided to apply for voluntary delisting from NASDAQ and deregistration from the SEC reporting requirements. The company plans to file Form 25 with the SEC on or about 10 days after Notice to NASDAQ, which will serve as formal notice to the SEC of intention to delist. The delisting will become effective 10 days after the Form 25 is filed with the SEC. The company's ongoing disclosure obligations under the Securities Exchange Act, including the obligation to file annual reports, will terminate on February 12, 2025, which will be 90 days after the filing of the Form 15-F with the SEC planned November 15, 2024. The company's ADR program is also expected to be terminated on January 21, 2025, in conjunction with the applications for NASDAQ delisting and SEC deregistration.
|
SANW | Hot Stocks16:39 EDT S&W Seed receives non-compliance notice from Nasdaq - S&W Seed received a notice from Nasdaq advising the company that its failure to timely file its Annual Report on Form 10-K for the fiscal year ended June 30, 2024 with the SEC is in contravention of Nasdaq Listing Rule 5250(c)and could serve as an additional deficiency and basis for the delisting of the company's securities from Nasdaq. The Company has 60 days from the date of the notice to submit a plan to regain compliance with the Filing Requirement for consideration by Nasdaq. The company intends to timely submit a plan, including, but not limited to, a timeline in which the Form 10-K will be filed. The Nasdaq Notice has no immediate effect on the listing of the company's common stock on the Nasdaq Capital Market. The company implemented a reverse stock split of its common stock at a ratio of 1-for-19 shares effective for marketplace purposes with the open of business on Friday, October 18. The company is subject to a separate review by Nasdaq to determine if the company is able to regain compliance with Nasdaq's $1.00 bid price requirement by November 11.
|
FRBA | Hot Stocks16:38 EDT First Bank receives regulatory approvals for new share repurchase program - The Board of Directors has authorized and the Bank has received regulatory approvals for a new share repurchase program. The program provides for the repurchase of up to 1.0 million shares of First Bank common stock for an aggregate repurchase amount of up to $16.0 million. The timing, price and volume of repurchases will be based on market conditions, relevant securities laws and other factors. The stock repurchases may be made from time to time on the open market or in privately negotiated transactions. The stock repurchase program does not require First Bank to repurchase any specific number of shares, and First Bank may terminate the repurchase program at any time. The share repurchase program will expire on September 30, 2025.
|
CBAN | Hot Stocks16:35 EDT Colony Bankcorp reports Q3 net interest margin 2.64% vs. 2.78% last year - CEO Heath Fountain says: "We are pleased with the improvement in operating results during the third quarter of 2024 and to see the continued progression in the performance of our complementary business lines alongside ongoing efficiency and expense discipline. We are also excited about our new digital banking platform rollout that occurred during the quarter. This enhanced platform will provide our customers with a state-of-the-art online banking experience which we believe will enable us to deliver solutions for all our customer's needs in today's digital environment. We had anticipated margin expansion in the second half of the year, but it did not materialize in the third quarter of 2024. However, we are pleased to report increased net interest income this quarter, and we believe that the margin has now reached its lowest point. We are optimistic about seeing improvement going forward as changes in the rate environment and easing from the Federal Reserve have allowed us to relieve pressure on our funding costs. Loan growth picked up slightly in the third quarter and overall asset quality remains strong. Our pipelines for both loans and deposits remain strong and our team has done a fantastic job of continuing to grow and build customer relationships."
|
WHR | Hot Stocks16:34 EDT Whirlpool backs FY24 cash from operating activities view of ~$1.05B - Backs FY24 free cash flow view ~$500M.
|
STBA | Hot Stocks16:32 EDT S&T Bancorp raises quarterly dividend to 34c per share - The Board of Directors of S&T Bancorp approved a 34c per share cash dividend on October 23. This is an increase of 1c, or 3.03%, compared to a cash dividend of 33c per share declared in the same period in the prior year. The annualized yield using the October 22 closing price of $38.75 is 3.51%. The dividend is payable November 21 to shareholders of record on November 7.
|
AWI | Hot Stocks16:31 EDT Armstrong World raises quarterly dividend 10% to 30.8c per share - Armstrong World Industries announced today that its Board of Directors has approved a 10% increase in the company's quarterly cash dividend to $0.308 per share of common stock. The dividend will be paid on November 21, 2024, to stockholders of record as of the close of business on November 7, 2024. "This announcement marks the sixth consecutive annual increase since we initiated our dividend program in 2018. This growth reflects our ability to generate free cash flow as well as the Board of Director's continued confidence in our long-term growth strategy," said AWI Senior Vice President and CFO Chris Calzaretta. "With our healthy balance sheet and track record of strong free cash flow growth, we remain committed to returning cash to shareholders as an important pillar of our capital allocation framework."
|
SRG... | Hot Stocks16:30 EDT Seritage Growth Properties makes $25M loan prepayment - Seritage Growth Properties (SRG) announced that on October 23, 2024, the Company has made a voluntary prepayment of $25 million toward its $1.6 billion term loan facility provided by Berkshire Hathaway Life Insurance Company of Nebraska (BRK.A). With the prepayments, the Company has now repaid a total of $1.345 billion since December 2021 and $255 million of the term loan facility remains outstanding. The current prepayments will reduce Seritage's total annual interest expense related to the term loan facility by approximately $1.75 million. The cumulative repayments since December 2021 have reduced Seritage's total annual interest expense related to the term loan facility by approximately $94.1 million.
|
NOW | Hot Stocks16:29 EDT ServiceNow introduces Workflow Data Fabric - ServiceNow" introduced Workflow Data Fabric, forging a new generation of AI-fueled productivity for the enterprise. Workflow Data Fabric is an enhanced integrated data layer that unifies business and technology data across the enterprise, powering all workflows and AI agents with real-time, secure access to data from any source. ServiceNow also announced Zero Copy connectors to optimize the company's integration capabilities so customers can turn data into instant, AI-powered action. Additionally, ServiceNow announced a strategic partnership with leading systems integrator Cognizant as the first partner to bring Workflow Data Fabric to market for customers. Workflow Data Fabric expands customers' ability to connect, understand, and act on any structured, unstructured, semi-structured, and streaming data from across the enterprise-both inside and outside of ServiceNow-for maximum scalability and efficiency. Extending the capabilities of Automation Engine and newly introduced database RaptorDB Pro, Workflow Data Fabric can access and update data from any system, allowing ServiceNow to not only read from these data repositories, but also take action. For example, retailers can use Workflow Data Fabric to access data from various systems-including their Customer Data Platform, core ERP, order management systems, POS systems, merchant trade rebates in Excel, and marketing receipts for co-op and trade spend-for a single, integrated view of their business that allows them to take action on customer inquiries, orders, and returns."
|
IBM | Hot Stocks16:29 EDT IBM CEO says Q3 performance led by double-digit growth in Software - "Our third-quarter performance was led by double-digit growth in Software, including a re-acceleration in Red Hat. We continue to see great momentum in AI as our models are trusted, fit-for-purpose, and lower cost, with performance leadership. Our generative AI book of business now stands at more than $3 billion, up more than $1 billion quarter to quarter," said Arvind Krishna, IBM chairman, president and chief executive officer. "Heading into the final quarter of 2024, we expect fourth-quarter constant currency revenue growth to be consistent with the third quarter, with continued strength in Software. We are confident in our ability to deliver more than $12 billion in free cash flow for the year, driven by continued expansion of our operating margins."
|
NOW | Hot Stocks16:28 EDT ServiceNow partners with databricks to deliver zero copy integration - ServiceNow "announced a Zero Copy partnership that supercharges machine learning and AI capabilities. Databricks' Delta Sharing will enable ServiceNow to offer Zero Copy, high-bandwidth, bi-directional, and secure integration with the Databricks Data Intelligence Platform so customers can turn data and insights into instant, AI-powered action. Bi-directional data exchange with the Zero Copy integration will allow Databricks customers to access data within the ServiceNow platform via ServiceNow's RaptorDB high-performance database to analyze, enhance, and combine different sets of company data. Additionally, ServiceNow customers will be able to access rich data and insights from Databricks to trigger workflows in ServiceNow. Databricks will also enable ServiceNow customers to build, test, and deploy custom GenAI applications tailored to their unique business needs. The partnership also amplifies ServiceNow's agentic AI workflow capabilities. Customers will be able to design and deploy AI-driven workflows on the ServiceNow platform that combine Databricks' AI capabilities with ServiceNow's workflow automation, creating predictive and self-optimizing business processes. This includes training custom models from Databricks and integrating them into the ServiceNow platform."
|
NOW SNOW | Hot Stocks16:28 EDT ServiceNow, Snowflake partner on Zero Copy integration - ServiceNow (NOW) and Snowflake (SNOW) announced a Zero Copy partnership that connects enterprise-wide data to help solve mission-critical problems at scale. The Zero Copy integration will leverage Snowflake's powerful enterprise AI platform to allow customers to trigger ServiceNow workflows directly from Snowflake. It will also support integrated, bi-directional Zero Copy data sharing between Snowflake and ServiceNow. By linking data-rich insights with operational actions, customers can increase decision speed and enterprise agility without the need to move data. Snowflake is already powering AI and data experiences for several hundred businesses across financial services, media, public sector, retail and telecom with the Snowflake Connector and will continue to expand on this customer value with the ServiceNow Spoke integration that is coming soon. This Zero Copy partnership will also extend this platform integration, which will further customers' ability to connect, understand, and leverage enterprise data assets for deeper business value.
|
NVDA NOW | Hot Stocks16:26 EDT ServiceNow partners with Nvidia to accelerate agentic AI adoption - ServiceNow (NOW) announced a major expansion to its strategic partnership with NVIDIA (NVDA) to accelerate enterprise adoption of Agentic AI. The companies will use NVIDIA NIM Agent Blueprints to co-develop native AI Agents within the ServiceNow platform, creating use cases fueled by business knowledge that customers simply choose to turn on. NVIDIA will collaborate with ServiceNow to map out multiple AI agent use cases. With six years of joint innovation on AI models, along with several previously announced strategic collaborations, ServiceNow and NVIDIA are reshaping how businesses integrate AI into their operations. The Now Platform is rapidly becoming a foundation for enterprise transformation in the evolving landscape of generative AI. By harnessing NVIDIA's advanced AI infrastructure-such as the NVIDIA AI Enterprise software platform, including the NVIDIA NeMo framework and NVIDIA NIM microservices running on NVIDIA DGX Cloud, and ServiceNow's leading AI platform for business transformation, this partnership is supercharging productivity and streamlining complex workflows across industries. "GenAI is a massive tailwind for our industry, and ServiceNow and NVIDIA are bringing the next wave of agentic AI to enterprises everywhere," said ServiceNow Chairman and CEO Bill McDermott. "The transformative potential of AI is unfolding for enterprises in real time. CEOs are looking to ServiceNow and NVIDIA to modernize their businesses and lead them into an AI-powered future. Together, our world-class product and engineering teams are shoulder-to-shoulder, putting AI to work for our customers."
|
PSO NOW | Hot Stocks16:25 EDT Pearson, ServiceNow collaborate over AI solutions for workforce deployment - Pearson (PSO) and ServiceNow (NOW) announced a global collaboration to supercharge workforce development and employee experiences in the age of AI. In the first phase of the multi-year deal, ServiceNow will collaborate with Pearson on research and insights that analyze how emerging technology will impact the global workforce and will use Credly by Pearson to issue accreditation and track skills development. Pearson will use ServiceNow's AI-powered Now Platform to boost employee productivity, efficiency, and talent retention.
|
QS | Hot Stocks16:24 EDT QuantumScape tightens FY24 adjusted EBITDA view to ($300M)-($380M)
|
PAG | Hot Stocks16:22 EDT Penske Automotive to acquire Porsche Centre Melbourne - Penske Automotive Group has signed an agreement to acquire Porsche Centre Melbourne, located in Melbourne, Australia, from Porsche Retail Group Australia Pty Ltd. Upon completion of the acquisition, Porsche Centre Melbourne will expand the Company's partnership with Porsche in Melbourne to deliver an exceptional level of customer experience. The acquisition is expected to add $130M in estimated annualized revenue, bringing the estimated annualized revenue for the three Porsche Dealerships in Melbourne to $260M. The acquisition is subject to customary conditions and is expected to close by the end of this year.
|
FTI | Hot Stocks16:21 EDT TechnipFMC announces additional $1B share repurchase authorization - TechnipFMC announced that its Board of Directors has authorized and declared a quarterly cash dividend of $0.05 per share, payable on December 4, 2024 to shareholders of record as of the close of business on the New York Stock Exchange on November 19, 2024, which is also the ex-dividend date. The Board has also authorized additional share repurchases of up to $1 billion. Together with the existing program, the Company is now authorized to repurchase shares of up to $1.2 billion, representing more than 10 percent of the Company's outstanding shares at today's closing price. Since the initial share repurchase authorization in July 2022, the Company has returned more than $740 million to shareholders through stock repurchases and dividends. Doug Pferdehirt, TechnipFMC's Chair and CEO, stated, "We remain confident in the outlook for our Company and now expect to nearly double shareholder distributions in 2024. Today's dividend declaration and significant increase to our share repurchase authorization further demonstrate our commitment to maximize shareholder value through the return of capital to our shareholders."
|
ACIC | Hot Stocks16:21 EDT American Coastal: Q4 net current accident quarter catastrophe losses ~$16.2M - American Coastal Insurance Corporation announced estimated hurricane losses for the 2024 third and fourth quarters. The Company estimates net current accident quarter catastrophe losses incurred stemming from Hurricanes Debby and Helene in the third quarter of 2024 to be approximately $3.8M , net of tax impacts. $2.4M of this impact from Helene is retained by AmCoastal, with $1.4M being retained by the Company's captive reinsurance entity. The Company does not expect losses from Debby or Helene to reach the excess of loss layers of AmCoastal's reinsurance program and expects to deliver positive net income for the third quarter of The Company estimates net current accident quarter catastrophe losses incurred stemming from Hurricane Milton in the fourth quarter of 2024 to be approximately $16.2M , net of tax impacts. $7.9M of this impact from Milton is retained by AmCoastal, with $8.3M being retained by the Company's captive reinsurance entity. The Company also expects to incur approximately $13M of reinstatement premiums that will be amortized as ceded premiums earned over the remaining eight month coverage period, from October 2024 through May 2025. "Hurricanes Helene and Milton were severe storms with devastating impact, and our primary focus is on servicing our policyholders. ACIC's underwriting discipline and robust reinsurance program serve to protect AmCoastal's balance sheet and reduce volatility from the active Atlantic hurricane season. We estimate a gross loss between $150 and $200M from Milton, leaving 100% of AmCoastal's $1.26B occurrence based reinsurance tower available for subsequent catastrophe events. With AmCoastal's reinsurance tower fully intact and a lower $10.3 million retention on potential second and third events, net of tax impacts, the Company remains strongly positioned for the remainder of the 2024 Atlantic hurricane season, and is expected to remain profitable in the fourth quarter, despite Milton's impact," said Brad Martz, President of American Coastal.
|
CHDN | Hot Stocks16:21 EDT Churchill Downs to invest $40M-$50M in HRM entertainment venue in Calvert City - Churchill Downs announced the planned development of a $40M to $50M historical racing machine, or HRM, entertainment venue in Calvert City, Kentucky. CDI plans to open the new 23,000 square-foot facility with 250 HRMs, a sports bar and a sportsbook, and a simulcast center in early 2026. The new facility will serve as an extension of Oak Grove Racing, Gaming and Hotel and will be CDI's eighth historical horse racing entertainment venue in the Commonwealth of Kentucky.
|
AMSF | Hot Stocks16:19 EDT Amerisafe declares special dividend of $3.00 per share - AMERISAFE announced that its Board of Directors had declared a special cash dividend of $3.00 per share. The special cash dividend will be payable on December 13, 2024, to shareholders of record as of December 6, 2024. The Board of Directors also declared a regular quarterly dividend of $0.37 per share, payable on December 13, 2024, to shareholders of record as of December 6, 2024.
|
MORN | Hot Stocks16:18 EDT Morningstar announces CFO Dubunsky will step down from his role - Morningstar announced Jason Dubinsky, chief financial officer, CFO, will step down from his role at the end of the year to pursue other interests. Dubinsky joined Morningstar in 2017 and has been the firm's chief financial officer for over seven years. Morningstar has initiated a succession process. Dubinsky will continue to serve as chief financial officer until Dec. 31, 2024, and will be engaged in a consulting role to support a smooth transition through June 30, 2025.
|
DFH | Hot Stocks16:15 EDT Dream Finders Homes to acquire Alliant National Title Insurance Company - Dream Finders Homes announced that it has entered into a definitive agreement to acquire Alliant National Title Insurance Company, Inc. and a related affiliate. Alliant National, based in Longmont, Colorado, is a title insurance underwriter with more than 700 independent agents in 32 states and the District of Columbia. Alliant National is the largest independent title underwriter in the country with no direct or affiliated operations. Patrick Zalupski, Dream Finders' Chairman and CEO, said, "This is a strategic acquisition for DFH and allows us to further vertically integrate alongside our existing title insurance agency business while facilitating growth in the title insurance marketplace. We are excited to partner with a successful and motivated Alliant National team and believe our homebuilding operations can add meaningfully to the bottom line of Alliant National, which will in turn benefit the bottom line of DFH." The closing of this transaction is subject to closing conditions, including insurance regulatory approvals.
|
NOW RMNI | Hot Stocks16:15 EDT ServiceNow, Rimini Street partner on new enterprise software model - ServiceNow (NOW) and Rimini Street (RMNI) announced an expanded partnership that enables organizations to unlock value in existing ERPs and enterprise applications to fund new innovation and growth. The new solution combines the power of the single architecture, single data model of ServiceNow with Rimini Street's proven enterprise software support, in order to accelerate customer innovation across procurement, finance, supply chain, HR, customer service and IT. "Twentieth century systems have created a mess of complexity that hinders 21st century innovation," said Bill McDermott, chairman and chief executive officer at ServiceNow. "ServiceNow's partnership with Rimini Street gives customers a more unified, intelligent platform to maximize their existing software investments, for faster paths to transformation. Together, we are enabling a brighter future where technology unlocks unprecedented potential."
|
WCN | Hot Stocks16:14 EDT Waste Connections raises quarterly dividend 10.5% to 31.5c per share - Waste Connections announced that its Board of Directors has declared a regular quarterly cash dividend on the company's common shares and approved a 10.5% increase in the dividend. The regular quarterly cash dividend, which increases to 31.5c per common share of the company from 28.5c per common share of the company, will be paid on November 21 to shareholders of record on the close of business on November 7. The Board intends to review the quarterly dividend each October, with a long-term objective of increasing the amount of the dividend.
|
TXT | Hot Stocks16:14 EDT Textron CFO Connor to retire February 28, 2025 - Textron announced that Frank T. Connor, executive vice president and chief financial officer, has notified the Company that he intends to retire on February 28, 2025. David Rosenberg, Textron's vice president, Investor Relations, has been elected to succeed Connor as executive vice president and chief financial officer, effective March 1, 2025. "On behalf of the Board of Directors, I would like to thank Frank for his outstanding leadership over the past 15 years," said Scott Donnelly, Textron chairman and chief executive officer. "We are grateful for the significant contributions he has made across Textron in helping to drive financial and operational excellence."
|
LC | Hot Stocks16:13 EDT LendingClub sees Q4 pre-provision net revenue $60M-$70M - Sees Q4 loan originations $1.8B-$1.9B.
|
ZWS | Hot Stocks16:12 EDT Zurn Elkay Water raises quarterly dividend 12.5% to 9c per share - Zurn Elkay Water Solutions Corporation announced that its Board of Directors declared a quarterly common stock dividend of $0.09 per share, reflecting a 12.5% increase from the prior quarterly dividend of $0.08 per share. The dividend is payable in cash on December 6, 2024 to stockholders of record as of November 20, 2024.
|
CP | Hot Stocks16:12 EDT Canadian Pacific Kansas City sees FY24 adjusted EPS up double digits vs. FY23 - Sees FY24 RTMs up mid single digits vs. FY23 on a combined basis.
|
TSLA | Hot Stocks16:07 EDT Tesla: Ahead of schedule on 29k H100 cluster at Gigafactory Texas
|
TSLA | Hot Stocks16:07 EDT Tesla says has sufficient liquidity to fund product roadmap - Tesla said: "Our company is currently between two major growth waves: the first one began with the global expansion of the Model 3/Y platform and we believe the next one will be initiated by advances in autonomy and introduction of new products, including those built on our next generation vehicle platform. Despite ongoing macroeconomic conditions, we expect to achieve slight growth in vehicle deliveries in 2024. Energy storage deployments are expected to more than double year-over-year in 2024. We have sufficient liquidity to fund our product roadmap, long-term capacity expansion plans and other expenses. Furthermore, we will manage the business such that we maintain a strong balance sheet during this uncertain period." Tesla said plans for new vehicles, including more affordable models, remain on track for start of production in the first half of 2025.
|
WULF | Hot Stocks16:05 EDT TeraWulf announces $200M share repurchase pact - TeraWulf announced that its Board of Directors approved a share repurchase program authorizing the Company to repurchase up to $200 million of the Company's outstanding shares of common stock through December 31, 2025.The share repurchase program reflects the Company's confidence in its business strategy and financial health. TeraWulf intends to repurchase shares using excess cash, prioritizing this initiative after disciplined capital expenditures aimed at supporting organic growth in HPC/AI and evaluating strategic opportunities, such as potential site acquisitions.
|
TSLA | Hot Stocks16:05 EDT Tesla sees slight growth in vehicle deliveries in 2024
|
TSLA | Hot Stocks16:05 EDT Tesla sees slight growth in vehicle deliveres in 2024
|
ALGN | Hot Stocks16:02 EDT Align Technology announces iTero intraoral scanner product innovations - Align Technology announced iTero intraoral scanner product innovations that provide an overall solution for general practitioner, GP, dentists. "The iTero intraoral scanner innovations introduced today will enable doctors to present a variety of options to their patients, supporting chairside education and communication, that helps deliver a great patient experience and supports patients making informed choices about their dental treatment in consultation with their doctor," said Karim Boussebaa, Align Technology executive vice president and managing director for the iTero scanner and services business.
|
LHX PLTR | Hot Stocks16:01 EDT L3Harris, Palantir announce strategic partnership - L3Harris (LHX) and Palantir Technologies (PLTR) announced a strategic partnership to propel advanced technology development and accelerate L3Harris' digital transformation. The companies' complementary capabilities - including L3Harris' sensors and software-defined systems and Palantir's Artificial Intelligence Platform - will together enable new levels of capability and resilient connectivity across the joint-all-domain network, ensuring warfighters can make more informed decisions faster to protect our nation's security and that of our allies. "As the industry's Trusted Disruptor, we are committed to collaborating with innovative partners to deliver unmatched value to our global customers," said Christopher E. Kubasik, Chair and CEO, L3Harris. "Our work to date has demonstrated the meaningful impact of integrating our capabilities, and we will build upon these efforts to enhance performance across domains."
|
ALGN | Hot Stocks16:00 EDT Align Technology introduces Invisalign Smile Architect - Align Technology announced the release of the next innovation of Invisalign Smile Architect software, now with Multiple Treatment Plans allowing doctors to visually compare and modify orthodontic only and ortho restorative treatment plans side-by-side. The Multiple Treatment Plans are integrated into ClinCheck treatment planning software for doctors to visually compare, review, and choose the best treatment option for each patient. "Invisalign Smile Architect with Multiple Treatment Plans was developed to help doctors facilitate patient education with treatment planning options for patient care to support more informed treatment decisions for their patients and ultimately enhance practice growth," said Sreelakshmi Kolli, Align Technology chief product and digital officer. "The advanced visual comparison tools within Invisalign Smile Architect software with Multiple Treatment Plans can help general dentists communicate treatment options that may combine orthodontic and restorative procedures to support doctors, patients, and their treatment goals."
|
KNX | Hot Stocks15:47 EDT Knight-Swift down about 1% heading into the close - Weakness in shares may be attributable to an early release of earnings that were due to be reported after the close.
|
DEO NKLA | Hot Stocks15:30 EDT DHL, Diageo team with deployment of Nikola hydrogen fuel cell trucks - DHL Supply Chain and Diageo North America (DEO) have announced plans to incorporate two fuel cell electric trucks, powered with hydrogen, to their U.S. fleet. The Class 8 trucks, manufactured by Nikola Corporation (NKLA), will be deployed and fueled with a HYLA modular refueler at the Diageo campus in Plainfield, Ill., marking a milestone for the state. DHL Supply Chain, Diageo North America's trusted contract logistics partner for over 20 years, has been actively working to develop innovative solutions that help to decarbonize its customers' logistics operations. The hydrogen fuel cell electric trucks are part of a broader sustainable supply chain strategy that has included use of battery electric vehicles, optimizing vehicle usage and routes, shifting to a multimodal approach, and increased use of US EPA SmartWay partner carriers. These efforts have resulted in year-over-year reductions in carbon dioxide emissions for both Diageo and DHL. "We are thrilled to integrate Nikola's hydrogen fuel cell electric trucks into our U.S. fleet," said Jim Monkmeyer, President of Transportation, DHL Supply Chain. "As a global logistics company with the goal of decarbonizing its business, we've integrated sustainability as a fourth strategic bottom line named "Green Logistics of Choice" in our newly announced Strategy 2030. The deployment of these fuel cell electric vehicles is one of many initiatives that demonstrates how we are putting action behind our words." Nikola's hydrogen fuel cell electric trucks offer a sustainable, and efficient alternative to traditional diesel-powered vehicles. Reference Link
|
ALTR SIEGY | Hot Stocks15:18 EDT Altair rises after Bloomberg reports Siemens in talks over potential deal - Shares of Altair Engineering (ALTR) are on the rise after Bloomberg's Katie Roof, Crystal Tse, and Dinesh Nair reported that Siemens (SIEGY) is in discussions over a potential deal to acquire the software maker, according to people familiar with the matter. The German company has tapped advisers as it weighs a move for Altair, the authors note, citing the people. Shares of Altair Engineering are up about 4% in afternoon trading. Reference Link
|
ESI | Hot Stocks15:13 EDT Element Solutions up 11% after Bloomberg says company exploring sale
|
BNS | Hot Stocks15:09 EDT Scotiabank cuts prime lending rate to 5.95% from 6.45% - Scotiabank announced that it is decreasing its Canadian dollar prime lending rate to 5.95% from 6.45%, effective October 24, 2024.
|
ICE | Hot Stocks14:58 EDT ICE reports over 190M contracts of interest rate derivatives traded in Q3 - Earlier on Wednesday, Intercontinental Exchange or ICE, announced record activity across its interest rate derivatives markets with over 190M contracts traded in Q3, surpassing the previous record set in Q1 2020. ICE's interest rate markets also hit record average daily volume or ADV, during the quarter with 2.9M contracts traded, up 39% year-to-date YTD . In the past quarter, a record 118M Euribor futures and options traded, exceeding the last high set in 2013. Euribor is the benchmark for managing short term euro-related interest rate risk. ICE Euribor futures and options ADV is up 28% this year. During September 2024, ADV across the interest rates complex exceeded 3.4M contracts, surpassing the previous monthly record set in May 2010. Meanwhile, SONIA futures, the benchmark for managing U.K. interest rate risk, traded a record 14 million contracts during the month, with ADV up 59% YTD and open interest up 65% year-over-year y/y. "The record trading activity reflects customers utilizing ICE as the only exchange globally to offer a diverse and deeply liquid derivatives complex across European rates," said Caterina Caramaschi, Vice President, Financial Derivatives at ICE. "As participants manage changing interest rate policy and exposure between central bank meeting dates, we are seeing heightened trading activity which is fueling liquidity."
|
PTON | Hot Stocks14:52 EDT Peloton strength attributed to Einhorn mention - Shares of Peloton are up 41c, or 7%, to $6.06, which is being attributed to positive comments said to be made by David Einhorn, who is presenting today at the Robin Hood Investors Conference. It was previously disclosed that David Einhorn's Greenlight Capital had acquired a stake in Peloton.
|
AMZN | Hot Stocks14:38 EDT Amazon??????s enhanced homepage features make shopping easier, personalized - Amanda Doerr, Vice President of Core Shopping at Amazon blogged in part, earlier: "Improvements include personalized recommendations, improved browsing, and streamlined reordering in time for the holiday shopping season. We love innovating to offer customers the best combination of selection, value, and convenience, and strive to set the industry standard for a world-class shopping experience. Our shopping experience is rooted in making customers' lives better and easier every day, leading us to invent features such as quick and easy shopping with Buy Now, customer reviews and more recently review highlights, and Rufus, our AI shopping assistant. We regularly make improvements to our store to help customers find the right products quickly-from personalizing product titles in search, to introducing visual search tools, to making it easier to learn about different types of products with AI Shopping Guides. When rolling out new features, we take an intentionally iterative approach, often testing multiple versions to ensure an easy and intuitive customer experience.We're adding to that list by testing new homepage features and design elements on the Amazon Shopping app for iOS and Android for millions of customers in the U.S. These features bring customers a more personalized and easy-to-navigate place to start their shopping and showcase products and services from across Amazon that reflect their interests and shopping habits. We're testing these new experiences with select customers and look forward to sharing with more U.S. customers in the coming months." Reference Link
|
RY | Hot Stocks14:33 EDT RBC Royal Bank cuts prime rate to 5.95% from 6.45% - RBC Royal Bank is decreasing its prime rate by 50 basis points from 6.45% to 5.95%, effective October 24, 2024.
|
APH | Hot Stocks14:26 EDT Amphenol seeing 'incremental tick-down' in Europe - On the company's Q3 earnings call, executives at Amphenol stated in part, according to a transcript of the event: "I will say that our view of the trends in Europe are probably a little more muted than maybe they were a quarter ago. I mean, we're pleased with what we've seen in North America and Asia. We we grew in industrial organically in both regions, both on a year-over-year basis and sequentially, but we probably have seen an incremental tick-down in Europe and what to look for there. I mean, I think we'll have to watch the automotive industry in the industry will the automotive market. Industrial market in Europe are fairly tight. As you know, well, you have a lot of factory automation and machine tool industry is in the life cycles that such a big fan economy. And so I think we'll have to watch that and see how it proceeds."
|
CNI... | Hot Stocks14:12 EDT North American rail traffic down down 0.6% for the week ending October 19 - The Association of American Railroads or, AAR, reported U.S. rail traffic for the week ending October 19. For this week, total U.S. weekly rail traffic was 510,730 carloads and intermodal units, up 1.1% compared with the same week last year. Total carloads for the week ending October 19 were 223,278 carloads, down 4.6% compared with the same week in 2023, while U.S. weekly intermodal volume was 287,452 containers and trailers, up 6% compared to 2023. Five of the 10 carload commodity groups posted an increase compared with the same week in 2023. They included grain, up 3,052 carloads, to 23,372; miscellaneous carloads, up 1,015 carloads, to 9,992; and farm products excl. grain, and food, up 898 carloads, to 18,082. Commodity groups that posted decreases compared with the same week in 2023 included coal, down 8,261 carloads, to 58,350; nonmetallic minerals, down 3,771 carloads, to 30,281; and metallic ores and metals, down 3,551 carloads, to 18,884. For the first 42 weeks of 2024, U.S. railroads reported cumulative volume of 9,142,601 carloads, down 3.3% from the same point last year; and 11,042,994 intermodal units, up 9% from last year. Total combined U.S. traffic for the first 42 weeks of 2024 was 20,185,595 carloads and intermodal units, an increase of 3.1% compared to last year. North American rail volume for the week ending October 19 on 9 reporting U.S., Canadian and Mexican railroads totaled 333,360 carloads, down 4.4% compared with the same week last year, and 368,573 intermodal units, up 3.1% compared with last year. Total combined weekly rail traffic in North America was 701,933 carloads and intermodal units, down 0.6% . North American rail volume for the first 42 weeks of 2024 was 28,077,581 carloads and intermodal units, up 2.3% compared with 2023....Publicly traded companies in the space include CN (CNI), CSX (CSX), Canadian Pacific Kansas City (CP), Norfolk Southern (NSC), Union Pacific (UNP), (TRN), Greenbrier (GBX), FreightCar America (RAIL), L.B. Foster (FSTR), Wabtec (WAB), GATX (GATX) and Rail Vision (RVSN)... Reference Link
|
GTIM | Hot Stocks14:12 EDT Good Times Restaurants buys Good Times stores in Broomfield, Northglenn - Good Times Restaurants Inc. announced that it has acquired the Good Times Burgers & Frozen Custard locations in Broomfield and Northglenn, Colorado, from a franchisee. The two restaurants were closed for two days for the installation of new digital menu boards at the walk-up window, installation of the brand's next-generation point-of-sale system and retraining of all the team members. These restaurants have reopened to serve guests with renewed excitement. Ryan Zink, President and CEO, said, "We are thrilled to add two more Good Times Burgers & Frozen Custard restaurants to our company owned and operated portfolio. We are also proud to have completed the menu board and point of sale initiatives throughout the state of Colorado. We expect the two acquired locations will be remodeled during the next eighteen to twenty-four months as part of our ongoing system refresh. We appreciate the wonderful customers in these great communities and look forward to earning their continued loyalty."
|
BDX | Hot Stocks13:04 EDT Becton Dickinson announces strategic collaboration with Ypsomed - Becton, Dickinson and Company announced a strategic collaboration with Ypsomed, a developer of injection systems, to advance self-injection solutions for high-viscosity biologic drugs. "In a joint project, Ypsomed and BD have pre-assessed and streamlined integration of the BD Neopak XtraFlow Glass Prefillable Syringe with Ypsomed's YpsoMate 2.25 autoinjector platform, addressing current limitations by enabling the delivery of higher viscosity biologic drugs in an autoinjector format," the companies stated. "Cross-supplier collaborations are vital in today's pharmaceutical ecosystem," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "These partnerships can help drive innovation and ensure that systems work by design and over lifecycles, allowing our pharmaceutical partners to get life-saving therapies to patients faster."
|
ZM | Hot Stocks12:21 EDT Zoom launches Zoom AI Companion 2.0 - Zoom launched Zoom AI Companion 2.0 on Wednesday, just weeks after announcing the next generation of Zoom AI Companion at Zoomtopia. AI Companion 2.0 is enhanced with additional capabilities to help expand context, synthesize information, and take action to give users time back in their day, so they can focus on meaningful work and building connections with team members, the company said. "We're thrilled with AI Companion's ability to help boost productivity throughout the workday. With our new capabilities, AI Companion has the power to help people make the most of their meetings, kickstart documents, get important information at a glance, and transform their workday," said Jeff Smith, head of product, Workplace AI, Meetings, and Spaces at Zoom. "And, the substantial added value that we're delivering today is just the beginning. Zoom is hyper-focused on customer experience, and in the coming weeks, we'll support broader queries across Zoom Workplace, improve response times, and enable AI Companion to take more actions for the user." Reference Link
|
COF DFS | Hot Stocks12:15 EDT Capital One, Discover move lower after Bloomberg report of NY AG probe
|
NEP | Hot Stocks12:04 EDT NextEra Energy Partners falls -15.3% - NextEra Energy Partners is down -15.3%, or -$3.84 to $21.25.
|
CSTM | Hot Stocks12:03 EDT Constellium falls -25.1% - Constellium is down -25.1%, or -$3.75 to $11.19.
|
DOCN | Hot Stocks12:02 EDT DigitalOcean announces strategic partnership with Hugging Face - DigitalOcean Holdings announced a strategic partnership with Hugging Face, an open-source and open science platform that helps users build, deploy and train machine learning models. The cornerstone of this new partnership will be the newly available 1-Click Models powered by Hugging Face HUGS, allowing users to quickly deploy third party models with DigitalOcean GPU Droplets, and performance powered by NVIDIA H100, accelerated computing.
|
ANRO | Hot Stocks12:02 EDT Alto Neuroscience falls -67.3% - Alto Neuroscience is down -67.3%, or -$9.78 to $4.75.
|
AAPL | Hot Stocks12:02 EDT Apple falls 2% after analyst Ming-Chi Kuo highlights cut iPhone orders - The shares are down 2% in midday trading to $231.37.
|
LAD | Hot Stocks12:01 EDT Lithia & Driveway rises 11.8% - Lithia & Driveway is up 11.8%, or $36.06 to $340.60.
|
JBT | Hot Stocks12:01 EDT JBT Corp. rises 12.1% - JBT Corp. is up 12.1%, or $11.57 to $106.83.
|
LRN | Hot Stocks12:00 EDT Stride rises 31.1% - Stride is up 31.1%, or $20.08 to $84.57.
|
EA... | Hot Stocks11:41 EDT U.S. video game spending fell 6% year-over-year in September, says Circana - Circana analyst Mat Piscatella said that projected U.S. total spending on video game hardware, content and accessories fell 6% during September 2024 when compared to a year ago. The decline was driven by a 44% drop in hardware spending and a 3% dip in content. 2024 year-to-date spending was flat when compared to the same period in 2023. Mobile content spending for the YTD period ending September was $1.7B higher than a year ago, while console content spending has fallen by $0.8B. Electronic Arts' (EA) "EA Sports FC 25" was September's best-selling video game in tracked spending, with double-digit percentage growth compared to "EA Sports FC 24" during its Sep 2023 launch month. "EA Sports FC 25" reached the highest U.S. launch month dollar sales of any soccer game released to date. Sony's (SONY) "Astro Bot" ranked as the #2 best-selling game of the month, debuting as the 25th best-seller of 2024 year-to-date. September video game hardware spending fell 44% when compared to a year ago, to $251M. This is the lowest monthly hardware spend total for a September month since 2019. PlayStation 5 again led the month's hardware market in unit and dollar sales, with Xbox Series (MSFT) ranking 2nd in dollars and Nintendo Switch (NTDOY) #2 in units sold. Xbox Series X consoles comprised 58% of total Xbox Series units sold in September, and account for the majority of Xbox Series units sold life-to-date. 40% of total PlayStation 5 hardware unit sales in September came from Digital PS5 consoles. Digital consoles now comprise 18% of total life-to-date unit sales of PS5 hardware. Other top-selling games in the U.S. for the month of September were EA's "Madden NFL 25" and "EA Sports College Football 25," Nintendo's "The Legend of Zelda: Echoes of Wisdom," Ubisoft's (UBSFY) "Star Wars Outlaws," Take-Two's (TTWO) "NBA 2K25," and Warner Bros. Discovery's (WBD) "Hogwarts Legacy."
|
GEV | Hot Stocks11:31 EDT GE Vernova intends to remove some blades from Vineyard Wind farm - GE Vernova and Vineyard Wind provided an update on the implementation of their Incident and Response and Action Plan announced in August. The plan outlined steps to safely remove the remainder of the damaged blade on turbine AW-38, remove any remaining debris, complete environmental studies, implement actions for blade readiness for service, and, ultimately, resume turbine installation and operations of the Vineyard Wind 1 project. With respect to removal of the AW-38 blade involved in the July event, GE Vernova committed to undertaking several tasks with Resolve Marine under supervision of a federal interagency. Those tasks included blade rotations to reduce blade debris, the removal of the hanging portion of the blade, clearing of debris from the platform, and addressing seabed debris. The first three tasks have been completed and the fourth, the removal of seabed debris, began on October 13, 2024, and will be completed this week. The final task, removal of the root of the blade from the rotor hub, is expected to occur in the coming weeks. Following the initial assessment of environmental impacts from the blade incident, GE Vernova laid out further plans to conduct a more comprehensive analysis. The plan outlined GE Vernova's three-stage approach to preparing blades for an anticipated return to service. After implementing extensive quality checks and out of an abundance of caution, GE Vernova intends to remove some blades from the Vineyard Wind farm while strengthening other blades as needed to support the safety and operational readiness of this project. Following authorization in mid-August to resume certain activities, eight new towers and nacelles have been installed on the project. On October 22, the companies were granted approval to return to installing new blades on turbines at the project once stringent safety and operational conditions are met. The companies will continue to make progress on these elements in upcoming weeks prior to installation. As GE Vernova and Vineyard Wind focus on these critical pathways, the final step in the action plan - operations and power production - will resume only after additional progress is made and all requisite approvals are granted. Reference Link
|
BA | Hot Stocks11:22 EDT Boeing: Walking away from defense contracts not the answer
|
BA | Hot Stocks11:14 EDT Boeing sees 'bumpy' return from supply chain post-strike
|
BA SPR | Hot Stocks11:11 EDT Boeing CEO says no change in commitment to Spirit AeroSystems deal
|
BA | Hot Stocks11:10 EDT Boeing says 'can't wave a wand and clean up' BDS contracts
|
BA | Hot Stocks10:58 EDT Boeing sees 1H25 cash usage, 2H25 cash positive - Sees calendar year 2025 as cash usage.
|
BA | Hot Stocks10:58 EDT Boeing: Financial outlook, long-term outlook under review
|
BA | Hot Stocks10:58 EDT Boeing intending to maintain $10B in cash on hand, says CFO
|
BA | Hot Stocks10:55 EDT Boeing CFO says has plan to address balance sheet in near-term - Says could include offering of equity and equity linked securities.
|
BA | Hot Stocks10:53 EDT Boeing in process of going through portfolio, says CEO
|
BA | Hot Stocks10:52 EDT Boeing sees Q4, 2025 as another use of free cash
|
BA | Hot Stocks10:50 EDT Boeing expects to burn cash in Q4, 2025
|
BA | Hot Stocks10:46 EDT Boeing says ended Q3 with 60 737-8 jets in inventory
|
BA | Hot Stocks10:46 EDT Boeing says 38 per month target for 737 production will be delayed
|
BA | Hot Stocks10:40 EDT Boeing CEO: 'Change is already underway'
|
BA | Hot Stocks10:37 EDT Boeing CEO says 'committed' to resetting relationship with IAM
|
BA | Hot Stocks10:36 EDT Boeing CEO says stabilizing the business 'central to my focus' since starting - Comments taken from Q3 earnings conference call.
|
ODFL | Hot Stocks10:29 EDT Old Dominion sees October revenue per day down from prior year - On the company's Q3 earnings call, Old Dominion stated: "On a sequential basis, our revenue per day for the third quarter decreased 1.9% when compared to the second quarter 2024, with LTL tons per day decreasing 3.2% and LTL shipments per day decreasing 1.0%. For comparison, the 10-year average sequential change for these metrics includes an increase of 3.6% in revenue per day and a 0.9% and LTL tons per day and an increase of 2.3% and LTL shipments per day. The modest sequential changes in LTL tons per day during the third quarter were as follows: you lost 4.4% as compared to June; August decreased 0.8% as compared to July, September increased 1.7% as compared to August. The 10 year average change for these respective months of 2.9% in July, an increase of 0.6% in August and an increase of 3.5 per temper for October. We expect our revenue per day will decrease approximately 11.2% to 7.8% when compared to October 2023, with a decrease of approximately 9.2% to 9.8% in our LTL tons per day. We will provide the actual revenue related details for October in our third quarter Form 10 Q."
|
BA | Hot Stocks10:27 EDT Boeing: 787 program currently producing at 4 per month - Maintains plan to return to producing 5 787s per months by year end. Comments taken from slides being presented on Boeing's Q3 earnings conference call.
|
AAPL GS | Hot Stocks10:25 EDT CFPB orders Apple, Goldman Sachs to pay over $89M for 'Apple Card failures' - The Consumer Financial Protection Bureau, or CFPB, has taken action against Apple (AAPL) and Goldman Sachs (GS) for "customer service breakdowns and misrepresentations that impacted hundreds of thousands of Apple Card users." The CFPB said it found that Apple failed to send tens of thousands of consumer disputes of Apple Card transactions to Goldman Sachs, and when Apple did send disputes to Goldman Sachs, the bank did not follow numerous federal requirements for investigating the disputes. Apple and Goldman launched Apple Card despite third-party warnings to Goldman that the Apple Card disputes system was not ready due to technological issues, CFPB added. These failures meant that consumers faced long waits to get money back for disputed charges, and some had incorrect negative information added to their credit reports. The CFPB is ordering Goldman Sachs to pay at least $19.8M in redress and a $45M civil money penalty, and Apple to pay a $25M civil money penalty. The CFPB is also banning Goldman Sachs from launching a new credit card unless it can provide a credible plan that the product will actually comply with the law. The CFPB also found that Apple and Goldman Sachs misled consumers about interest-free payment plans for Apple devices. Many customers thought they would automatically get interest-free monthly payments when buying Apple devices with their Apple Card. Instead, they were charged interest. In some cases, Apple did not even show the interest-free payment option on its website on certain browsers. Goldman Sachs also misled consumers about the application of some refunds, which led to consumers paying additional interest charges.Reference Link
|
AAPL GS | Hot Stocks10:11 EDT CFPB fines Apple, Goldman for credit card 'customer service breakdowns' - Tthe Consumer Financial Protection Bureau announced an action against Apple (AAPL) and Goldman Sachs (GS) "for customer service breakdowns and misrepresentations that impacted hundreds of thousands of Apple Card users." The CFPB "found that Apple failed to send tens of thousands of consumer disputes of Apple Card transactions to Goldman Sachs, and when Apple did send disputes to Goldman Sachs, the bank did not follow numerous federal requirements for investigating the disputes." Apple and Goldman launched Apple Card "despite third-party warnings to Goldman that the Apple Card disputes system was not ready due to technological issues. These failures meant that consumers faced long waits to get money back for disputed charges, and some had incorrect negative information added to their credit reports," the agency said in a statement. The CFPB is ordering Goldman Sachs to pay at least $19.8M in redress and a $45M civil money penalty, and Apple to pay a $25M civil money penalty. The CFPB is also banning Goldman Sachs from launching a new credit card unless it can provide a credible plan that the product will actually comply with the law. Reference Link
|
UXIN | Hot Stocks10:04 EDT Uxin Ltd trading resumes
|
PRG | Hot Stocks10:00 EDT Prog Holdings falls -9.3% - Prog Holdings is down -9.3%, or -$4.36 to $42.62.
|
CSTM | Hot Stocks10:00 EDT Constellium falls -17.4% - Constellium is down -17.4%, or -$2.60 to $12.32.
|
ANRO | Hot Stocks10:00 EDT Alto Neuroscience falls -61.5% - Alto Neuroscience is down -61.5%, or -$8.94 to $5.59.
|
DQ | Hot Stocks10:00 EDT Daqo New Energy rises 9.8% - Daqo New Energy is up 9.8%, or $2.04 to $22.86.
|
JBT | Hot Stocks10:00 EDT JBT Corp. rises 10.2% - JBT Corp. is up 10.2%, or $9.71 to $104.97.
|
LRN | Hot Stocks10:00 EDT Stride rises 29.9% - Stride is up 29.9%, or $19.30 to $83.79.
|
SHEL | Hot Stocks09:59 EDT Shell to acquire combined-cycle power plant in priority U.S. trading market - Shell Energy North America , or SENA, a subsidiary of Shell plc, has signed an agreement to acquire a 100% equity stake in RISEC Holdings, , or RISEC, which owns a 609-megawatt two-unit combined-cycle gas turbine power plant in Rhode Island. "This acquisition secures long-term supply and capacity offtake for Shell in the deregulated Independent System Operator New England (ISO New England) power market, where SENA has held a contract with RISEC under an energy conversion agreement for 100% of the plant's energy offtake since 2019. RISEC's combined-cycle gas turbine power plant supplies power to the ISO New England power market, where demand is expected to increase in coming decades due to growing decarbonisation efforts in sectors such as home heating and transportation. The acquisition will be absorbed within Shell's cash capital expenditure guidance, which remains unchanged. The transaction is subject to regulatory approvals and is expected to close in Q1 2025," the company stated. "Shell has had a successful integrated gas and power business in the growing ISO New England market for over 20 years, and this acquisition secures valuable trading opportunities by guaranteeing SENA's position in the market," said Huibert Vigeveno, Shell Downstream, Renewables & Energy Solutions Director. "Our strong understanding of this plant's performance positions Shell to capitalise on its value within our existing trading portfolio."
|
GD | Hot Stocks09:56 EDT General Dynamics says 'very strong' balance sheet - Feels "pretty good" about current capital structure.
|
UXIN | Hot Stocks09:54 EDT Uxin Ltd trading halted, volatility trading pause
|
TRU | Hot Stocks09:48 EDT TransUnion rises 4.9% - TransUnion is up 4.9%, or $5.22 to $111.00.
|
DQ | Hot Stocks09:48 EDT Daqo New Energy rises 7.1% - Daqo New Energy is up 7.1%, or $1.48 to $22.30.
|
LRN | Hot Stocks09:47 EDT Stride rises 30.0% - Stride is up 30.0%, or $19.34 to $83.83.
|
NEP | Hot Stocks09:47 EDT NextEra Energy Partners falls -8.8% - NextEra Energy Partners is down -8.8%, or -$2.21 to $22.88.
|
CSTM | Hot Stocks09:47 EDT Constellium falls -19.1% - Constellium is down -19.1%, or -$2.85 to $12.08.
|
ANRO | Hot Stocks09:47 EDT Alto Neuroscience falls -62.8% - Alto Neuroscience is down -62.8%, or -$9.13 to $5.40.
|
GD | Hot Stocks09:43 EDT General Dynamics says pipeline 'pretty robust' in Combat Systems - Sees "good margin performance" in Combat Systems going forward.
|
GLT BERY | Hot Stocks09:34 EDT Glatfelter shareholders approve proposals related to Berry Global deal - Glatfelter Corporation (GLT) and Berry Global Group (BERY) announced that Glatfelter's shareholders have approved all matters relating to the merger of Berry's Health, Hygiene and Specialties Global Nonwovens and Films business with Glatfelter required to be approved by Glatfelter shareholders, as described in the proxy statement/prospectus provided to its shareholders in connection with the Special Meeting. At the Special Meeting of Glatfelter Shareholders held earlier today, Glatfelter shareholders voted to approve the share issuance proposal, the charter amendment proposals, the omnibus plan proposal and the advisory compensation proposal. The transaction is expected to close on November 4, subject to the satisfaction or waiver of the closing conditions for the transaction. As previously announced, in connection with the merger, Glatfelter will effect a reverse stock split and change its name to Magnera Corporation. The Board of Directors of Glatfelter approved a final reverse stock split ratio of 1-for-13. Accordingly, Glatfelter announced today that it will effect a 1-for-13 reverse stock split of its common stock, par value $0.01 per share, that it expects will become effective on November 4, at 12:01 AM Eastern Time, before the opening of trading on the New York Stock Exchange. Glatfelter's common stock will begin trading on the New York Stock Exchange on a split-adjusted basis when the market opens on November 4.
|
USAP | Hot Stocks09:27 EDT Universal Stainless & Alloy tied to fatal crash last year, Hunterbrook says - Universal Stainless & Alloy is set to be acquired by Aperam S.A. in early 2025, notes Hunterbrook Media, which also says that a U.S. Air Force Safety Investigation Board report leaked to the media shows that "Universal Stainless is behind a fatal Osprey crash in Japan that killed eight U.S. airmen, and potentially at least five prior aircraft failures." Universal has a history of quality control issues going back at least as far as 2001, claims Hunterbrook Media, which notes that based on Hunterbrook Media's reporting, Hunterbrook Capital is short Universal Stainless at the time of publication of its report. Reference Link
|
GD | Hot Stocks09:26 EDT General Dynamics sees FY24 Aerospace revenue ~$12.3B - Sees FY24 Marine Systems revenue ~$13.9B.
|
GD | Hot Stocks09:21 EDT General Dynamics sees Q4 free cash flow greater than 100% of net income
|
CYCC | Hot Stocks09:21 EDT Cyclacel reports clinical data from Phase 2 study of oral fadraciclib - Cyclacel Pharmaceuticals announced that initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101 clinical study of fadraciclib, or "fadra", as a single agent was presented as a poster at the 2024 EORTC-NCI-AACR 36th Symposium on Molecular Targets and Cancer Therapeutics, in Barcelona, Spain. The patients were enrolled in the biomarker-enriched, Cohort 8 of the proof of concept study and were preselected for CDKN2A and/or CDKN2B abnormalities. Fadraciclib was well tolerated in Cohort 8. Most common drug-related adverse events included diarrhea, nausea, vomiting and were similar to those seen at this dose in Phase 1. There were no Grade 3 or higher treatment-emergent adverse events in the Phase 2 study this far, consistent with the Phase 1 data. The majority of patients had ECOG performance status of 1 and median number of prior therapies was 3. In Cohort 8, four patients had pancreatic cancer, and one each cholangiocarcinoma, duodenal, melanoma, cervical, laryngeal, ovarian, squamous cell cancer with unknown primary and thymus cancer. Out of six patients evaluable for efficacy, two achieved stable disease: a melanoma patient whose treatment duration was 125 days and a squamous cell CUP patient who achieved 11% tumor shrinkage in the sum of all lesions on first scan with treatment duration of over 85 days. Two additional patients with ovarian and laryngeal cancer are ongoing but have not had their first scan yet. The most common molecular characteristics of Cohort 8 patients were loss of function or deletion of CDKN2A and/or CDKN2B tumor suppressor genes. Other pharmacogenomic observations included CDKN2A/B, KRAS and/or TP53 mutations. Two Phase 2 dose expansion cohorts in the 065-101 study were initiated. Cohort 8 prospectively enrolled 12 patients with known CDKNA/B genetic alterations between April and September 2024. The rationale was to further evaluate observations of clinical activity in Phase 1 patients with known CDNK2A or CDKN2B genetic alterations. Cohort 6 is enrolling patients with T-cell Lymphoma with two patients treated so far. The rationale was to further evaluate observations of partial response in 2/3 Phase 1 patients with T-cell lymphoma. Certain T-Cell lymphomas are known to harbor CDNK2A genetic alterations. All patients were treated with oral fadraciclib 100mg BID, M-F, week 1-4 in 28-day cycles which was the Recommended Phase 2 dose. The primary objectives of the 065-101 study in the Dose Escalation stage are to determine maximum tolerated dose and/or RP2D and in the Phase 2, Proof of Concept stage to evaluate preliminary efficacy of fadraciclib as measured by overall response rate. The secondary objectives in Dose Escalation are to assess safety and tolerability, pharmacokinetics, and ORR, while in Phase 2, Proof of Concept, to assess safety and tolerability, evaluate disease control rate, duration of response, progression free survival, and overall survival. The study is utilizing a Simon two-stage optimal design to evaluate clinical activity. Exploratory objectives include investigation of clinical pharmacodynamics and pharmacogenomics.
|
GD | Hot Stocks09:18 EDT General Dynamics says 'generating solid operating leverage' - Says three of four business segments in Q3 had revenue increases vs. the prior year. Expects to deliver ~42 G700's in 2024, with 27 in Q4. Expects "reasonably strong" order intake in Q4. Says demand "remains solid" across Combat Systems segment. Says supply chain "not getting better at a fast enough pace." Comments taken from Q3 earnings conference call.
|
HLT | Hot Stocks09:18 EDT Hilton sees 2025 looking 'a lot like' 2024 from same-store growth point of view
|
HLT | Hot Stocks09:17 EDT Hilton: Q4 RevPar to be partially offset by election, ongoing labor disputes
|
HLT | Hot Stocks09:16 EDT Hilton sees net unit growth 6%-7% for FY25
|
HLT | Hot Stocks09:15 EDT Hilton sees FY24 net unit growth 7%-7.5%
|
HLT | Hot Stocks09:15 EDT Hilton: Weekday pace for October tracking up more than 300bps vs. September
|
HLT | Hot Stocks09:14 EDT Hilton expects to return approximately $3B to shareholders for the FY - Comments taken from Q3 earnings conference call.
|
SATX | Hot Stocks09:14 EDT Satixfy Communications signs $10M in agreements - SatixFy Communications announced that it has signed new agreements in aggregate valued at $5M, alongside an immediate prepayment of a previously announced $5M associated with an amendment to an existing contract with MDA Space. Agreements signed further the significant collaboration between the two companies initiated in October 2023. Under an amendment to the original master purchase agreement, signed in October 2023, a total of $3M was added to the scope of the original agreement, alongside an immediate prepayment of $5M that was previously announced but not yet paid. Additionally, an authorization to proceed agreement was signed between SatixFy and MDA Space, which is structured around two milestone payments totaling $2M in the aggregate and setting out the terms for future purchase orders.
|
DLPN | Hot Stocks09:13 EDT Dolphin Entertainment's Special Projects supports Academy Museum Gala 2024 - Dolphin subsidiary Special Projects played a pivotal role in overseeing talent at the Academy Museum of Motion Pictures' fourth annual gala, which raised over $11 million to support the museum's exhibitions, education initiatives, and public programming. The star-studded event honored Paul Mescal, Rita Moreno, and Quentin Tarantino for their contributions to film, while also featuring a performance by Cynthia Erivo. The gala, presented in partnership with Rolex, was co-chaired by Dr. Eric Esrailian, Salma Hayek Pinault, Nicole Kidman, Eva Longoria, and Tyler Perry.The Academy Museum of Motion Pictures, which held its fourth annual gala this year, raised over $11 million to support the museum's exhibitions, education initiatives, and public programming, including screenings, K-12 programs, and access initiatives in service of the general public and the local community of Los Angeles.
|
WYY | Hot Stocks09:11 EDT WidePoint awarded over $15.2M in contracts, renewals in Q3 - WidePoint was awarded approximately $15.2 million in contract awards and renewals during the third quarter of 2024. Jin Kang, WidePoint's CEO, stated: "Q3 2024 confirms that each of WidePoint's solution lines is gaining market momentum. We are proud that our offerings are being recognized by commercial and government enterprises as the preferred technology partner for managing and securing devices, staff and mobile environments. We are excited to see this momentum continuing through Q4 2024 and into 2025." Highlights include: More than 39 contractual actions resulting in approximately $15.2 million in contract value; Approximately $3.2 million in commercial contracts; Approximately $12 million in government contracts; New orders for WidePoint's MobileAnchor Derived Digital Credentials from federal defense and civilian agencies; Multi-year managed technology services contracts; Multiple commercial MMS contracts including leading transportation, insurance and healthcare companies; A major mobility management program for a new federal civilian agency client went live after months of implementation, marking the success of another strategic partnership
|
NWVCF | Hot Stocks09:10 EDT EnWave signs license, equipment purchase agreement with CNTA of Spain - EnWave announced that it has signed a license agreement, equipment purchase agreement and a referral agreement with CNTA, the Spanish National Centre for Food Technology and Safety. CNTA is a private non-profit association that aims to contribute towards improving the competitiveness and quality of the Spanish food sector. The license grants the R&D rights to CNTA to use EnWave's proprietary Radiant Energy Vacuum dehydration technology in collaboration with their many current and future clients. The Equipment Purchase made by CNTA is for a 10kW REV machine that will showcase their state-of-the-art facility with the value proposition of REV technology.
|
MU NVDA | Hot Stocks09:08 EDT Micron says SSDs qualified for recommended vendor list on Nvidia GB200 NVL72 - Micron Technology (MU) announced that its 9550 PCIe Gen5 E1.S data center SSDs have been added to the NVIDIA (NVDA) recommended vendor list for the NVIDIA GB200 NVL72 system and its derivatives. The GB200 NVL72 uses the GB200 Grace Blackwell Superchip to deliver rack-scale, energy-efficient AI infrastructure. The enablement of PCIe Gen5 storage in the system makes the Micron 9550 SSD an ideal fit for optimizing performance and power efficiency in AI workloads like large-scale training of AI models, real-time trillion-parameter language model inference and high-performance computing tasks.
|
UPST | Hot Stocks09:08 EDT Washington-based credit union WECU selects Upstart for personal lending - WECU, a Washington-based credit union with over 160,000 members and over $2.7B in assets, has announced a new partnership with Upstart the leading artificial intelligence AI lending marketplace, to provide personal loans to new and existing members. "At WECU, we believe that lives can be transformed through smart, responsible lending practices. That's why we're thrilled to partner with Upstart," said Matt Berendsen, VP of Lending at WECU. "By partnering with Upstart, we are expanding access to fair and accessible loans that align with our mission of improving the financial well-being of our members and our community." "We are proud to have WECU in the family of Upstart lending partners," said Michael Lock, Senior Vice President of Lending Partnerships at Upstart. "In partnership with Upstart, WECU is able to extend its reach beyond its direct members, helping more Washington State residents access the capital they need to improve their lives."
|
LXRX | Hot Stocks09:08 EDT Lexicon announces new analysis of Phase 3 SCORED trial - Lexicon Pharmaceuticals announced a new analysis of its Phase 3 SCORED clinical trial demonstrating the protective effects of sotagliflozin in patients with diabetic kidney disease, DKD. Data will be presented at Kidney Week 2024, the annual meeting of the American Society of Nephrology in San Diego, California. Details for the presentation are as follows: Within the entire cohort of 10,574 participants, a placebo-adjusted acute decline in eGFR of -2.59 ml/min/1.73m2/year was observed. The total placebo-adjusted slope was -0.08 ml/min/1.73m2/year. Compared to placebo, sotagliflozin had a greater benefit on chronic slope with increasing baseline albuminuria.
|
VZ | Hot Stocks09:07 EDT Verizon Frontlie launches two new deployable asset prototypes - Verizon Frontline announced the launch of two new deployable asset prototypes designed to support the mission-critical communications needs of first responders during public safety operations. Created as part of the Verizon Frontline Innovation Program, the newly-developed Off-Grid, Cross-Communications Network trailer, or OXEN, and Emergency Response Incident Command Center vehicle, or ERICC, are the latest deployable assets available for use by public safety agencies via the Verizon Frontline Crisis Response Team. Recently, both were deployed in support of public safety agencies in Milwaukee, Wisc., at the Republican National Convention, and in Chicago at the Democratic National Convention. The OXEN is a ruggedized trailer built to provide first responders with a full range of Verizon Frontline connectivity options, including 5G Ultra Wideband, 4G LTE and satellite backhaul. The asset also offers mobile edge compute capabilities and radio interoperability. The OXEN can be powered by solar, shoreline power, or a diesel generator. The ERICC is a retrofitted vehicle built to provide first responders who don't have their own command center with a functional mobile workspace for three to five people, giving them better situational awareness during emergency response operations and the ability to establish off- grid communications.
|
GVP | Hot Stocks09:06 EDT GSE Systems announces Glass Lewis recommended shareholders to vote FOR merger - GSE Solutions announced that independent proxy advisory firm Glass Lewis & Co. recommended that GSE shareholders vote "FOR" the approval of the Agreement and Plan of Merger, dated as of August 8 by and between GSE, Nuclear Engineering Holdings LLC, and Gamma Nuclear Merger Sub. In its October 17 report recommending approval of the Merger Proposal, Glass Lewis stated: "Based on the Company's disclosure of the background leading up to the Merger Agreement, we believe the Company undertook a reasonably comprehensive strategic review here." "[C]onsidering the Company's recent financial struggles, we believe the proposed merger represents a compelling option, as it will provide certainty of value and a meaningful market premium to the Company's shareholders." In relation to October stock acquisitions, Glass Lewis further notes that while Bradley Radoff very recently acquired a stake in the Company, "[he] has yet to submit an alternative actionable proposal to the Company" and GSE shareholders should "be mindful of the fact that Mr. Radoff acquired his entire initial equity stake in the Company in October 2024, more than three weeks after the record date of [the special] meeting ." Therefore, Glass Lewis cautions, "Mr. Radoff and his affiliates will not be eligible to vote at [the special] meeting."
|
SVMH | Hot Stocks09:06 EDT SRIVARU announces expansion into Indian State of Kerala - SRIVARU Holding announced its expansion into the Indian State of Kerala with the launch of its PRANA 2.0 electric motorcycle through a new joint dealership with Electrogreen Motors in Thiruvananthapuram, Kerala's capital. The joint dealership model, developed by SRIVARU, allows the Company to partner with established local dealers, leveraging their resources and market reach. This approach enables SRIVARU to expand rapidly while minimizing upfront costs and ensuring capital efficiency. The new dealership in Kerala will offer SRIVARU's flagship electric motorcycles, the PRANA 2.0 Grand and PRANA 2.0 Elite.
|
SIFY | Hot Stocks09:06 EDT Sify Technologies launches GPU cloud CloudInfinit+AI - Sify Technologies announced the launch of GPU Cloud, CloudInfinit+AI Platform offering GPU-as-a-Service. Sify CloudInfinit+AI offer Enterprise cloud users GPU-as-a-Service. This platform is a tangential leap over Sify's existing portfolio of services. GPU-as-a-Service is a cloud-based offering that provides users with access to powerful Graphics Processing Units on a pay-as-you-go basis. This service is designed to support compute-intensive tasks such as machine learning, deep learning, model training, inferencing, data analytics, rendering, and scientific simulations, which require significant processing power. Key Features of the service will be Scalability where users can scale their GPU resources both ways, allowing for flexibility in handling varying workloads without the need for significant capital investment in hardware, accessibility of high-performance computing to a wider range of users, including startups and small businesses that may not have the resources to invest in expensive GPU infrastructure and the cost-effectiveness of using a subscription model. Importantly, GPU-as-a-Service democratizes access to high-performance computing resources, enabling organizations to leverage advanced technology for innovation and efficiency.
|
CSTM | Hot Stocks09:05 EDT Constellium sinks 18% to $12.28 after Q3 results, outlook miss estimates
|
GMM | Hot Stocks09:05 EDT Global Mofy signs strategic cooperation agreement with Haizhou district - Global Mofy AI announces recently, a delegation led by Chairman and CEO Haogang Yang engaged with local enterprises and government leaders, conducting an in-depth exploration of Lianyungang's digital economy, artificial intelligence, and cultural tourism resources. The visit resulted in the signing of a strategic cooperation framework agreement with Lianyungang's Haizhou High-Tech District, a district focused on supporting the broader digital economy and industries within.
|
APPF | Hot Stocks09:04 EDT AppFolio unveils FolioSpace resident experience, acquires LiveEasy for $80M - AppFolio unveiled FolioSpace, a next-generation resident experience that redefines how property managers and renters connect throughout the entire resident journey. FolioSpace will enable AppFolio's 20,000 property management customers to create a unified and elevated experience for the millions of residents they serve - from application through renewal. To accelerate its resident vision, on October 22, 2024 AppFolio acquired all of the outstanding shares of LiveEasy, a concierge platform providing moving and home services. By vertically integrating LiveEasy and offering its services as part of FolioSpace Resident Onboarding, AppFolio will reduce the stress of moving, deliver increased convenience, and save renters time and money. FolioSpace reimagines how property managers engage with residents by bringing the entire resident journey into one application. By streamlining tasks and communication, FolioSpace replaces traditional manual processes with intuitive digital workflows, including: Resident Application & Screening: A seamless application and approval process for applicants while providing property managers the data they need to select trusted residents and protect themselves from fraud. Resident Onboarding: A configurable digital checklist to streamline leasing and welcome new residents, plus with LiveEasy, access to savings and dedicated support in setting up their utilities, internet and cable, and moving services. Resident Services Marketplace: A collection of essential services to improve residents' living experience, while also creating value for property managers. Resident Inbox: A reimagined inbox gives residents a central location to communicate with their property managers for everything from maintenance requests to leasing questions. Property managers can use AppFolio Realm-X Messages, which leverages the power of genAI, to help them sort through, act on, and respond to routine resident communications. LiveEasy is the trade name of Move EZ, Inc., which AppFolio acquired via merger for approximately $80M, subject to customary adjustments.
|
SO | Hot Stocks09:04 EDT Southern Company announces retirement of Chief Information Officer Martin Davis - Southern Company announced the retirement of Martin B. Davis as executive vice president and Chief Information Officer, effective April 1, 2025. Davis has spent more than 35 years leading complex technology organizations in highly regulated environments. Since joining the company in 2015, Davis has led more than 2,000 technology professionals supporting Southern Company's subsidiaries.
|
RTX | Hot Stocks09:03 EDT Raytheon awarded $676M contracts for its TOW weapon system by US Army - Raytheon, an RTX business, was awarded $676M to continue manufacturing the tube-launched, optically-tracked, wireless-guided TOW weapon system for the U.S. Army. The two separate awards comprise an annual production contract for $430M in FY23 and an additional $246M award in 2024. Raytheon continues to improve TOW's design with modernized fuzing and target detection. These upgrades were recently demonstrated in successful Fly-To-Buy lot acceptance tests of the latest TOW 2B variant of the missile. Improvements to the overall missile design and packaging will help meet the latest military environmental requirements to support evolving logistical and terrain challenges. This testing milestone ensures TOW users around the world have the latest and most effective weapon system for their deterrence and defensive needs.
|
NOK | Hot Stocks09:02 EDT Nokia selected by LEARN to deploy new network, foster research in Texas - Nokia announced its collaboration with The Lonestar Education and Research Network, LEARN, the statewide Research and Education Network for the state of Texas, to upgrade LEARN's existing packet platform. The collaboration is part of LEARN's strategic NextGen Network initiative, which aims to replace routers across the LEARN backbone and modernize the existing statewide network, significantly advancing the network's infrastructure and the ability to serve its members. Nokia's solution will enhance the levels of scalability, security, and reliability over a 400GE backbone, as part of a broad project redesign led by LEARN to serve its more than 300 organizations that directly or indirectly rely upon its network.
|
KRON | Hot Stocks09:00 EDT Kronos Bio announces preclinical data from p300 KAT inhibitor program - Kronos Bio announced preclinical data from its p300 KAT inhibitor program for human papillomavirus-driven tumors at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Kronos Bio is exploring the utility of its p300 KAT inhibitor, KB-9558, for HPV-driven tumors. In the presentation, the authors show that the HPV genome preferentially integrates into transcriptionally active regions in the human genome where it becomes dependent on p300 to drive expression of its E6 and E7 oncogenes. It is widely recognized that elevated transcription of HPV E6 and E7 genes promotes degradation of tumor suppressors p53 and Rb. Importantly, inhibition of p300 KAT activity was highly selective in repressing the transcription of E6 and E7, which in turn led to restoration of the p53 and Rb pathways and drove anti-tumor effects through apoptosis and inhibition of uncontrolled tumor cell growth. In the presentation titled, "Oncogenic human papillomavirus hijacks p300 to drive viral transcription, creating a therapeutic vulnerability that can be exploited with selective p300/CBP catalytic inhibitors", the authors describe the experiments that led to the following key findings: HPV integrates into the human genome at specific locations where p300 regulates transcription; p300 inhibition demonstrated specific and potent reduction of expression of HPV oncogenes E6 and E7, both at the RNA and protein level; Loss of E6 and E7 led to restoration of p53 and Rb tumor suppressor pathways which led to the upregulation of p53 activated genes and downregulation of Rb repressed genes; Re-expression of E6 and E7 from an exogenous lentiviral vector where viral oncogene transcription is not mediated by p300 KAT activity reversed the effects of p300 KAT inhibition on p53 restoration and anti-tumor effects; These findings support the potential of KB-9558, a p300 KAT inhibitor, to treat HPV-driven tumors given its potential to suppress E6 and E7 expression and restore the p53 pathway
|
KO | Hot Stocks08:58 EDT Coca-Cola: Consumer, economies relatively stable on a global scale
|
INFY META | Hot Stocks08:57 EDT Infosys strengthens collaboration with Meta Platforms - Infosys (INFY) strengthened its collaboration with Meta (META) to drive innovation in generative AI through open-source initiatives. Infosys is a strong proponent of open-source software and remains steadfast in its commitment to democratizing AI. Leveraging Meta's Llama stack, a family of open-source large language models and tools, Infosys is driving significant advancements in AI and fostering innovation across industries. To accelerate adoption of Meta's Llama stack and spur innovation, Infosys also unveiled a Meta center of excellence focused on accelerating enterprise AI integration while supporting internal adoption and contributions to open-source communities. This center will enable a large pool of talent on the Llama stack, develop industry-specific use cases, and collaborate closely with Meta to help customers seamlessly adopt the Llama stack.
|
CMBT | Hot Stocks08:56 EDT CMB launches reopening of public takeover bid for CMB.TECH - CMB.TECH NV announces that today CMB NV has reopened its Belgian public takeover bid on all shares in CMB.TECH not already owned by CMB or persons affiliated with it, in accordance with applicable Belgian law, and concurrently is making a new U.S. offer in accordance with applicable U.S. federal securities laws, addressed to U.S. shareholders within the meaning of Rule 14d-1(d) under the Securities Exchange Act of 1934, as amended. The acceptance period of the Reopening opens on October 23 and closes on November 21 at 4 p.m. CET, or 10 a.m. New York City time. "The bid price of the Reopening amounts to $12.66 per share, i.e. $18.95 per share as increased, reduced by distributions totaling $6.29 per share. In the supplement to its response memorandum, the supervisory board of CMB.TECH unanimously recommends that shareholders do not tender their shares in the Reopening," the company noted. Reference Link
|
T | Hot Stocks08:54 EDT AT&T seeing 'better than expected returns' on fiber investments
|
T | Hot Stocks08:47 EDT AT&T expects higher capital investment in Q4 - Expects FY24 capital investments at "high end" of $21B-$22B range.
|
LQR | Hot Stocks08:45 EDT LQR House announces first shipment of SWOL Tequila for LCBO review - LQR House announced the shipment of its first batch of SWOL Tequila for analysis by the Liquor Control Board of Ontario. This marks a significant step for LQR House as it begins its international expansion and entry into the Canadian market. The shipment of SWOL Tequila will undergo a thorough analysis by the LCBO, which oversees alcohol regulation in the province. This regulatory analysis is expected to take approximately six weeks. Once SWOL Tequila is cleared for distribution across Ontario by the LCBO, the Company's distributor, Of The Earth Distribution Corp. is expected to start distribution in the province.
|
IDAI | Hot Stocks08:44 EDT Trust Stamp enhances biometric security with palm enhanced cytographic solution - Trust Stamp announce the launch of a pioneering research initiative aimed at expanding its biometric cryptosystem, Stable IT2, to include contactless palm authentication. The Biometric Secure Module, BSM, project will further enhance security by integrating face and palm biometrics, providing a more resilient and privacy-centric authentication system.
|
TVGN MSFT | Hot Stocks08:44 EDT Tevogen AI joins Microsoft for Startups - Tevogen Bio (TVGN) announces its Artificial Intelligence effort, Tevogen AI, has joined Microsoft (MSFT) for Startups. This partnership marks a significant milestone for Tevogen, providing unparalleled access to Microsoft's extensive ecosystem. The partnership is set to accelerate and streamline the development of Tevogen's proprietary algorithms, significantly advancing our mission to lower the total cost of drug development, expedite drug discovery, and deliver life-changing therapies to large patient populations. Mittul Mehta, CIO and Head of Tevogen AI commented "The leadership at Tevogen Bio is extremely optimistic about the future for Tevogen as a partner with Microsoft. Joining Microsoft for Startups underscores Microsoft's conviction in Tevogen's ability to not only innovate, but also deliver." The partnership with Microsoft, the leading innovator in the AI space, is a substantial investment in Tevogen's goal to provide affordable and accessible therapies. By leveraging Microsoft's cutting-edge AI technology, Tevogen aims to push the boundaries of what AI can achieve in the biotech industry.
|
MGNI DIS | Hot Stocks08:43 EDT Magnite, Disney announce two-year deal renewal - Magnite (MGNI) and Disney (DIS) have announced a two-year deal extension. As the relationship grows into its sixth year, Magnite continues to be Disney's preferred supply-side technology partner. Disney leverages Magnite's technology to monetize its ad-supported inventory across the company's entire portfolio. Magnite facilitates transactions for all 30+ DSPs that Disney works with.
|
VMEO AAPL | Hot Stocks08:42 EDT Vimeo launches spatial app for Apple Vision Pro - Vimeo (VMEO) announced the launch of its app for Apple Vision Pro (AAPL). This immersive app brings viewers into the content and empowers Vision Pro users to view, upload, and share their spatial videos with others to enjoy. The free app is now available to download on the visionOS App Store. With its ability to add remarkable depth and dimension to a scene, spatial video delivers a way to tell powerful stories, as it offers a more engaging and immersive experience for both personal and professional use cases. Spatial videos can be recorded on Apple Vision Pro, the iPhone 16 line, iPhone 15 Pro and iPhone 15 Pro Max. Canon has also announced the development of a new stereoscopic lens, the RF-S7.8mm F4 STM DUAL Lens, compatible with the popular EOS R7 camera body that will capture gorgeous spatial video.
|
KO | Hot Stocks08:42 EDT Coca-Cola CEO: External environment to continue to have 'many moving pieces'
|
CDZI | Hot Stocks08:42 EDT Cadiz and RIC Energy to build California's largest green hydrogen facility - Cadiz and RIC Energy, a global renewable energy company, announced they have entered into an agreement to build California's largest green hydrogen facility at Cadiz Ranch in the Mojave Desert. Under the agreement, Cadiz will supply land and water to RIC Energy for the creation of industrial quantities of 100% green hydrogen using solar energy. Rail lines, pipelines and interstate highways that intersect Cadiz Ranch will deliver green hydrogen to Southern California markets to fuel zero-emission trucks, cars and electric generation. RIC Energy chose the Cadiz area for its first US facility after a six-month diligence process that evaluated several locations across the state. Plans call for a self-sufficient, integrated, off-grid green hydrogen production facility utilizing photovoltaic solar for its power supply on up to 3,000 acres of the Cadiz Ranch. The new facility is expected to feature a combination of state-of-the-art technologies to create green hydrogen, complying with the strictest regulations of IRA's Section 45V, using on-site Cadiz water resources and fully renewable electricity generated from a local solar array. Cadiz will supply up to 500 acre-feet of water per year for hydrogen production. Cadiz, in turn, will be able to use green hydrogen and solar to power its water supply and groundwater banking operations. When operating at full capacity, the clean energy facility will produce 50,000 kilograms of hydrogen per day to fuel zero-emission trucks and cars, as well as be able to supply to many other California industries currently using fossil hydrogen. Plans call for on-site electricity storage along with equipment to compress and liquefy the hydrogen for rail or road transportation. The site at Cadiz is also ideal for possible future hydrogen pipelines serving the Los Angeles region. The hydrogen can also be blended locally with natural gas for transport via on-site and nearby existing gas transmission pipeline networks, with the objective of serving California's burgeoning hydrogen market and meeting California's mandate to deliver 90% clean electricity by 2035. According to ARCHES, its projects are expected to create over 200,000 green jobs in California and are forecast to generate $2.95B per year in economic value beginning in 2030, including significant health and healthcare cost savings from reduced pollution.
|
T | Hot Stocks08:42 EDT AT&T says targeting net debt to adjusted EBITDA in 2.5x range in 1H25 - Targeting incremental run-rate cost savings target of $2B+ by mid-2026. Says financial flexibility "continues to improve." Says investing for long-term growth, 5G and fiber. Expects seasonally higher phone purchasing activity in Q4. Expects strong finish to year. Comments taken from Q3 earnings conference call.
|
DJT AMZN | Hot Stocks08:42 EDT Trump Media announces launch of Truth+ streaming on Amazon Fire TV - Trump Media & Technology (DJT) announces that it has successfully launched an app for Amazon (AMZN) Fire TVs to access the Truth+ streaming platform.
|
TPET | Hot Stocks08:41 EDT Trio Petroleum appoints James Blake to board of directors - Trio Petroleum announced the appointment of James Blake to its Board of Directors. James is a Chartered Financial Analyst, with a distinguished career, having recently retired from a major Canadian bank where he managed over $750 million in assets as a portfolio manager.
|
ICU | Hot Stocks08:40 EDT SeaStar Medical announces Stanford Medicine is cleared to enroll subjects - SeaStar Medical announces that Stanford Medicine is cleared to actively enroll subjects in the NEUTRALIZE-AKI pivotal trial. With the recent addition of two Department of Defense medical centers, 12 sites are now activated to enroll subjects in the trial with enrollment at 52. "It goes without saying that Stanford is an incredibly important site," said Kevin Chung, MD, Chief Medical Officer of SeaStar Medical. "The recent decision by the U.S. Centers for Medicare and Medicaid Services to reimburse certain expenses for Medicare patients enrolled in this trial is proving critical in recruiting new medical sites. We are delighted that Stanford will be working with us to help change the standard of care for our most critically ill patients."
|
GLT BERY | Hot Stocks08:40 EDT Glatfelter shareholders approve proposals related to merger of Berry business - Glatfelter Corporation (GLT) and Berry Global Group (BERY) announced today that Glatfelter's shareholders have approved all matters relating to the merger of Berry's Health, Hygiene and Specialties Global Nonwovens and Films business with Glatfelter required to be approved by Glatfelter shareholders, as described in the proxy statement/prospectus provided to its shareholders in connection with the Special Meeting. At the Special Meeting of Glatfelter Shareholders held earlier today, Glatfelter shareholders voted to approve the share issuance proposal, the charter amendment proposals, the omnibus plan proposal and the advisory compensation proposal. The transaction is expected to close on November 4, 2024, subject to the satisfaction or waiver of the closing conditions for the transaction. As previously announced, in connection with the merger, Glatfelter will effect a reverse stock split and change its name to Magnera Corporation The Board of Directors of Glatfelter approved a final reverse stock split ratio of 1-for-13. Accordingly, Glatfelter announced it will effect a 1-for-13 reverse stock split of its common stock, par value $0.01 per share, that it expects will become effective on November 4, 2024 at 12:01 AM Eastern Time, before the opening of trading on the New York Stock Exchange. Glatfelter's common stock will begin trading on the New York Stock Exchange on a split-adjusted basis when the market opens on November 4, 2024, under a new CUSIP number, 55939A 107.
|
FAMI | Hot Stocks08:39 EDT Farmmi granted 180 days by Nasdaq for compliance with minimum bid price - Farmmi announced that on October 22, it received notification from The Nasdaq Stock Market confirming the Company has been granted an additional 180 calendar day period for compliance under its minimum bid price requirement through April 21, 2025. To regain compliance with NASDAQ's minimum bid price requirement, the closing bid price of the Company's ordinary shares needs to be at least $1.00 per share or greater for at least ten consecutive business days by April 21, 2025.
|
APRE | Hot Stocks08:39 EDT Aprea Therapeutics presents preliminary results on APR-1051 - Aprea Therapeutics announced that preliminary safety results on its WEE1 inhibitor APR-1051 are highlighted in a poster being presented today at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place in Barcelona, Spain. Data are available on two of three patients, with a cutoff date of October 7, 2024: Preliminary results demonstrate that APR-1051 is safe and well-tolerated with no hematologic toxicity; Hemoglobin, hematocrit, and platelet counts were stable or increased slightly during the first treatment cycle; There were no signs of neutropenia, with white blood cells and neutrophils trending up for both patients during the first treatment cycle; All adverse events recorded were Grade 1 and 2, with one Grade 1 AE possibly related to APR-1051; No QT prolongation has been observed; Three patients have been dosed to date with data available on two of these. One had disease progression at 49 days, a second withdrew following 36 days of treatment and dosing is ongoing in the third patient.
|
TZOO | Hot Stocks08:38 EDT Travelzoo announces 1M share repurchase plan - Travelzoo announced that its board of directors has authorized a new program to repurchase up to 1M shares of the company's outstanding common stock.
|
BLIN CRM | Hot Stocks08:37 EDT Bridgeline Digital announces global manufacturer, distributor chose HawkSearch - Bridgeline Digital (BLIN) announced a leading manufacturer and distributor of life safety gear, equipment, and training for first responders and law enforcement selected HawkSearch to improve their on-site search and merchandising powered by Salesforce (CRM) Commerce Cloud. The distributor will use HawkSearch to enhance website performance by delivering a more tailored search experience.
|
RZLV | Hot Stocks08:37 EDT Rezolve AI announces significant update to BRAiN Assistant - Rezolve Ai announced a significant update to its BRAiN Assistant, introducing several new features and improvements designed to enhance the user experience and the effectiveness of responses. This latest refresh underscores Rezolve's commitment to leveraging cutting-edge technology to deliver superior AI-driven solutions. The BRAiN Assistant serves as the consumer-facing showcase of Rezolve Ai's technology capabilities. The platform has already attracted over 58,000 users during its pilot, demonstrating its robust performance and user appeal. Key Features of the Updated BRAiN Assistant: Routing Algorithm for Optimal AI Model Selection: The BRAiN Assistant now utilizes a sophisticated routing algorithm to choose the best AI language model based on prompt analysis. This ensures that the most appropriate AI model is selected for each specific query, significantly improving the accuracy and relevance of the responses. Model Variety and Custom Solutions: The assistant employs multiple AI models and selects the one that best fits the nature and type of query. For commerce-related queries, the assistant prefers its custom-built model called brainpowa, which is specifically tailored to handle such requests efficiently and effectively. Real-Time Internet Search: Another significant enhancement is the capability to search internet sources in real-time. This allows the assistant to process and incorporate the latest information quickly, ensuring that users receive the most up-to-date and accurate answers. Independence from Specific AI Providers: The system does not rely on any particular AI provider or model. This, combined with the routing algorithm, offers greater flexibility and adaptability by utilizing various AI models as needed.
|
SIDU | Hot Stocks08:37 EDT Sidus clears design review for Netherlands laser comm satellite - Sidus Space announced the successful completion of the critical design review for LizzieSat NL, a laser communication satellite contracted by The Netherlands Organization TNO. This milestone not only validates the technical baseline for the satellite design but also triggers a milestone payment as part of the multimillion-dollar agreement. The CDR milestone locks the space vehicle technical baseline, affirming LizzieSat NL's readiness to proceed with flight-unit fabrication, assembly, system integration and testing. The completion of the major milestone moves the program closer to demonstrating TNO's HemiCAT, a high-efficiency miniature communications laser terminal, integrated into Sidus' hybrid 3D printed satellite platform, LizzieSat. As part of the agreement with TNO, Sidus will manage all aspects of integration, deployment and on-orbit operation for HemiCAT. "We are thrilled to achieve this critical milestone in the LizzieSat NL program, which not only advances our partnership with TNO but also demonstrates the value of our adaptable solutions and positions us at the forefront of innovation," said Carol Craig, CEO of Sidus Space. "This milestone brings Sidus closer to harnessing the transformative power of laser communications, significantly improving data transfer rates and unlocking new opportunities for our customers."
|
STLA | Hot Stocks08:37 EDT Stellantis presents $29.5M investment in upgraded wind tunnel - Stellantis unveiled its Moving Ground Plane, or MGP, technology, a $29.5M investment, at the company's research and technical center in Auburn Hills, Michigan. The upgraded wind tunnel will be able to measure and reduce airflow resistance from wheels and tires, which can account for up to 10% of total real-world aerodynamic drag. Optimizing aerodynamic efficiency is crucial in the effort to extend the driving range of electrified vehicles on a single charge. This enhancement directly contributes to improved efficiency, benefiting customers with longer EV ranges and potentially reducing battery sizes, which in turn could lead to cost and weight savings. Changes to wheelbase and track testing, which can take as much as two hours in conventional wind tunnels, can now be done in minutes. The upgraded facility is part of an estimated $85M commitment included in the 2019 UAW contract. It includes a new annex for staging test vehicles and a new outbuilding to support the MGP system, which uses high-pressure compressed air to drive the wheel and center belts at speeds up to 140 mph. The entire process is carefully controlled by electromechanical actuators. The measuring platform and turntable that comprise the heart of the MGP equipment weighs 137 tons, rests on a concrete foundation and are supported by a specially designed steel frame. The wind tunnel, capable of generating wind speeds of more than 160 mph, has been in continuous operation since 2002.
|
LMFA | Hot Stocks08:36 EDT LM Funding appoints Ryan Duran as president, US Digital Mining and Hosting - LM Funding America announced the promotion of Ryan Duran from Vice President of Operations to President of its digital mining subsidiary, US Digital Mining and Hosting Co. With this promotion, Ryan Duran will play a pivotal role in shaping the strategic direction and enhancing the operational efficiency of the Company's mining operations, ensuring that LM Funding remains at the forefront of the rapidly evolving cryptocurrency industry.
|
RUN ED | Hot Stocks08:34 EDT Sunrun builds, operates NY residential power plants with Orange and Rockland - Sunrun (RUN) and Orange and Rockland Utilities, a wholly owned subsidiary of Consolidated Edison (ED), have successfully activated New York's, NY, largest residential power plant using more than 300 solar-plus-storage systems. During dozens of peak electricity demand events this summer, the home batteries supplied stored solar energy to help stabilize the electric grid. "This is an important step toward the future of fortifying New York's energy grid, utilizing innovation to build a more affordable and reliable way to deliver power. We are excited to see residents of New York benefit from the sharing of stored solar power and know this partnership with Orange and Rockland will show the path forward for the rest of the state," said CEO of Sunrun, Mary Powell.
|
STEM | Hot Stocks08:34 EDT Stem names Albert Hofeldt CTO - Stem announced Albert Hofeldt as Stem's CTO, reporting to interim CEO, David Buzby, effective immediately. In his prior role as the company's executive VP of Technology, Hofeldt has led the responsibilities of advancing the company's technology innovation since 2022 and will further advance Stem's delivery of AI-enabled software solutions for the clean energy market as Stem's CTO.
|
KO | Hot Stocks08:33 EDT Coca-Cola CEO: Business trends improved each month during the quarter - Comments taken from Q3 earnings conference call.
|
CELU | Hot Stocks08:33 EDT Celularity files amended compliance plan with Nasdaq Hearings Panel - Celularity has requested a hearing before the Nasdaq Hearings Panel the Nasdaq Listing Qualifications Department's determination regarding Celularity's non-compliance with Nasdaq Listing Rule 5250(c)(1) and to seek an additional extension to regain compliance. As previously announced, Celularity received formal notice from Nasdaq on August 22, 2024, indicating non-compliance with the Rule due to the delayed filing of its quarterly reports on Forms 10-Q for the periods ended March 31, 2024, and June 30, 2024. On September 5, 2024, Celularity submitted an updated compliance plan to Nasdaq, and Nasdaq subsequently granted Celularity an extension until October 14, 2024, to regain compliance with the Rule. On October 16, 2024, Nasdaq notified Celularity that, as the Forms 10-Q had not been filed within the extension period, Celularity would be suspended from trading on The Nasdaq Capital Market at the opening of business on October 25, 2024, unless an appeal was filed by October 23, 2024. On October 23, 2024, Celularity timely filed an appeal and amended compliance plan with the Hearings Panel and requested a hearing, which temporarily stays suspension or delisting action. Celularity also requested that the stay remain in effect through the hearing process and any additional extension period granted by the Hearings Panel. Celularity remains committed to regaining compliance, having filed its Form 10-Q for the period ended March 31, 2024, on October 16, 2024, and is in the final stages of preparing its Form 10-Q for the period ended June 30, 2024. The Hearings Panel has the discretion to grant Celularity up to an additional 180 days to regain compliance, but there is no assurance that Celularity's appeal will be successful or that Celularity will regain or maintain compliance with the Rule or other Nasdaq listing requirements.
|
RTX | Hot Stocks08:33 EDT Collins Aerospace signs contract with Air Europa - Collins Aerospace, an RTX (NYSE: RTX) business, announced it has signed a 10-year contract with Air Europa to provide comprehensive maintenance, repair and overhaul, or MRO, services for the airline's fleet of 787 aircraft. Through its FlightSense and DispatchSM combined asset and MRO programs, Collins will supply Air Europa with onsite support for a number of 787 systems, including electric power, environmental control, avionics, lighting and cargo. In addition, Collins will provide predictive health maintenance through its Ascentia software platform and expand its pool of 787 spares in Europe. Collins' FlightSense and Dispatch programs offer maintenance agreements tailored to airlines' specific operational requirements. Ascentia, a cloud-based solution, uses advanced data analytics and machine-learning algorithms to help airlines improve maintenance operations and increase reliability. Together, FlightSense, Dispatch and Ascentia are part of Collins' larger MRO ecosystem, combining parts, systems and expertise to deliver more effective data-driven services to customers.
|
ORKT | Hot Stocks08:33 EDT Orangekloud, ELITC enter partnership agreement - Orangekloud Technology announced signing a partnership agreement with the Electronics Industries Training Centre, ELITC, a premier institute offering training and educational programs in Singapore. Highlights of the Partnership Agreement: Appointment of ELITC as the Preferred Training Partner in Singapore; Equipping the Workforce for Digital Transformation; Leveraging ELITC's Network for Wider Adoption of eMOBIQ Solutions
|
IRDM | Hot Stocks08:29 EDT Eutelsat America, OneWeb announce partnership agreement with Iridium - Eutelsat America Corp. and OneWeb Technologies, operating in combination as a wholly owned independent U.S. proxy company and subsidiary of Eutelsat Group, announced a partnership agreement with Iridium Communications to provide Iridium Certus and Iridium Satellite Time and Location services to U.S. government customers. EACOWT will now offer an enhanced GNSS-resilient Low Earth Orbit Ku-Band/L-band solution by adding Iridium Certus and Iridium STL services to its portfolio of government services. The solution will enable EACOWT to offer resilient connectivity, alongside out-of-band management solutions for remote terminals.
|
MKC | Hot Stocks08:28 EDT McCormick expects $8B in annual net sales by 2028 - McCormick & Company held an Investor Day at the company's Global Headquarters in Hunt Valley, Maryland. Brendan M. Foley, President and CEO, along with members of McCormick's leadership team shared plans to drive sustainable growth by leveraging its competitive advantages and successfully executing on its proven strategies. McCormick reaffirmed all components of its 2024 Outlook which was previously announced on October 1 during its earnings call. The Company anticipates achieving the mid to high-end of its projected Net Sales growth range and the high-end of its adjusted earnings per share range for 2024. McCormick expects 2025 to be a year of continued momentum supported by the effectiveness of its 2024 prioritized investments. The Company anticipates volume growth in-line with its organic long-term growth objective. The Company also expects to drive margin improvement and profitability growth rates closer to its long-term objectives. McCormick reaffirmed its long-term growth objectives for Net Sales of 4%-6%, Operating Income of 7%-9%, and EPS of 9%-11%. The Company expects to achieve these objectives, at the low end, on a compounded annual growth rate basis over the five-year period ending 2028, without the benefit of acquisitions. The Company expects to reach at least $8B in annual Net Sales by 2028.
|
GAME | Hot Stocks08:27 EDT GameSquare's Stream Hatchet launches AI-powered Influencer Discovery Tool - Stream Hatchet announced the launch of its AI-Powered Influencer Discovery Tool, designed to redefine how brands identify and connect with creators that resonate with their target audiences. This AI-powered solution marks a significant breakthrough in influencer marketing by using proprietary algorithms to sift through data on over 50 million creators to find the most aligned partners for brand campaigns. As brands seek innovative ways to maximize their marketing impact, traditional methods of influencer discovery have proven inefficient and unable to capture the nuanced fit required for lasting partnerships. Stream Hatchet's new AI Discovery Tool addresses this gap by leveraging machine learning to evaluate both quantitative and qualitative creator attributes, ensuring that clients are not only finding the most popular creators, but those whose content style, audience engagement, and values align with the brand's messaging.
|
VTAK | Hot Stocks08:26 EDT Catheter Precision to showcase data on VIVO technology at SCRN meeting - Catheter Precision announced that there will be two presentations showcasing the VIVO technology at the International Society for Cardiac Robotic Navigation Meeting October 28-29 in Lisbon, Portugal. The 2024 program highlights VIVO in the presentations. The first is October 28 and is titled "Robotics in VT plus non-invasive 3D mapping" by Dr. Jack Griffiths from the Royal Brompton Hospital in London. This presentation will focus on his experience with VIVO to include his previously published data about time savings. The second presentation is by Peter van Dam, PhD on October 29 and is titled "Non-invasive Mapping Using Individual Anatomy". Peter is the original engineer supporting the development of VIVO and will be presenting about the benefits of VIVO, which uses patient specific inputs, over other non-invasive mapping systems that do not. The third presentation, also on October 29, is presented by Dr. Leonor Perriera where she will provide update on the VIVO European Registry which has recently concluded. The data will include acute success and success at 12 month follow-up of the ventricular ablation.
|
GFS NXPI | Hot Stocks08:25 EDT GlobalFoundries, NXP Semiconductors to deliver next-gen 22FDX solutions - GlobalFoundries (GFS) and NXP Semiconductors (NXPI) announced collaboration to drive next-generation solutions across a range of end markets including automotive, IoT and smart mobile devices. This collaboration leverages GF's 22FDX process technology platform and global manufacturing footprint to optimize the power, performance and time-to-market of NXP's solutions. GF's 22FDX chips will be manufactured in Dresden and Malta, New York, providing NXP geographically diverse supply for their customers.
|
UPXI | Hot Stocks08:24 EDT Upexi to file Form 10-K on November 1 - Upexi received a Non Compliance Letter from The Nasdaq Stock Market due to the Company's failure to timely file its Form 10-K Annual Report for the period ended June 30, 2024, in violation of Nasdaq Listing Rule 5250(c)(1). The Company failed to timely file due to circumstances beyond its control, and intends to file its Form 10-K Annual Report on or before Friday, November 1, 2024. In addition, on October 17, 2024, the Company received written notice from Nasdaq informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on the Nasdaq Stock Market maintain a minimum bid price of $1.00 per share. Nasdaq notified the Company in the Compliance Notice that, from October 3, 2024 to October 16, 2024, the closing bid price of the Company's common stock had been $1.00 per share or greater and, accordingly, the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2) and that the matter was now closed.
|
FTCI | Hot Stocks08:24 EDT FTC Solar to supply 1GW of projects for Sandhills Energy - FTC Solar announced that FTC will be supplying its innovative 1P Pioneer trackers for 1 gigawatt of projects over three sites. The projects include a 448-megawatt project in Burt County, Nebraska, a 320-megawatt project in Cass County, Nebraska, both about 50 miles outside of Omaha, and the previously announced 225-megawatt project in Butler County, Nebraska. Yann Brandt, FTC Solar's President and CEO, commented, "We're looking forward to supporting these projects with our Pioneer 1P tracker and continuing to grow our relationship with Sandhills Energy. Market interest in Pioneer continues to grow, driven by key features such as its fast assembly time, high energy density, reduced pile count, and shorter embedment depth."
|
ACHV | Hot Stocks08:23 EDT Achieve Life Sciences CMO speaks at FDA, NIH Smoking Cessation Public Meeting - Achieve Life Sciences announced that Dr. Cindy Jacobs, Achieve's President and Chief Medical Officer, presented at the U.S. Food and Drug Administration and the National Institutes of Health Joint Public Meeting on "Advancing Smoking Cessation: FDA and NIH Priorities" held on October 21, 2024. The public meeting was initiated by Robert Califf, M.D., who currently serves as the 25th Commissioner of the FDA. The meeting included other representatives from the FDA, the NIH, the National Institute on Drug Abuse, and key academic and industry organizations with the stated focus of the meeting on accelerating innovation to advance treatments for smoking cessation. "We are appreciative that the FDA and NIH are making an effort to bring together experts who share a common goal of reducing the number of lives lost every year due to smoking-related diseases," stated Dr. Jacobs. "It has been nearly two decades since a new prescription smoking cessation treatment has been approved by the FDA. Cytisinicline is currently the only nicotine dependence treatment in late-stage development. We have completed two randomized Phase 3 clinical trials in over 1,600 subjects demonstrating robust evidence supporting safety and efficacy, based on the gold-standard clinical endpoint of continuous smoking cessation. We are currently working to complete a longer-term safety exposure study in subjects and look forward to our continued engagement with the FDA as we move towards our NDA filing and potential approval." Dr Jacobs was one of 10 participants at the meeting selected to deliver a 4-minute presentation. In her presentation Dr. Jacobs reminded the attendees that cytisine has been a smoking cessation treatment for decades in Eastern and Central Europe. She also pointed out that although the efficacy and safety profile has been well-established for this older marketed product, the treatment involves a complex 25-day titration regimen. Dr. Jacobs highlighted Achieve's redevelopment of this drug into a novel treatment for nicotine addiction, now known as cytisinicline. This new cytisinicline product features a revised formulation and tablet strength, easier streamlined dosing schedule, and extended treatment durations, demonstrating strong efficacy and excellent safety in the completed Phase 3 trials. In closing, Dr. Jacobs urged the FDA to re-assess how new drugs are being approved for smoking cessation treatment, especially given that no new prescription medications have been approved in nearly two decades, versus how other new nicotine or tobacco products are being approved in the US.
|
WINT | Hot Stocks08:23 EDT Windtree Therapeutics completes national phase filings for istaroxime - Windtree Therapeutics announced that the Company has completed national phase filings of patent applications around the world, including in the United States, Germany, France, Italy, Japan and China. "Windtree continues to prepare for the potential of istaroxime in treating cardiogenic shock patients by expanding and strengthening our patent estate," said Craig Fraser, Chairman and Chief Executive Officer of Windtree. "Unique aspects of istaroxime are utilized in our strategy for intellectual property and positive clinical development has helped bring these aspects to light."
|
NA | Hot Stocks08:22 EDT Nano Labs announces results of annual general meeting - Nano Labs announced the results of the Company's Annual General Meeting held at 10 A.M. on October 23, 2024, Beijing time. The proposals submitted for shareholder approval at the AGM have been approved. Specifically, the shareholders have passed the following resolutions: to effect a share consolidation of every ten shares with a par value of $0.0002 each in the Company's issued and unissued share capital into one share with a par value of $0.002, so that immediately following the Share Consolidation and the share re-designation, the authorized share capital of the Company shall be $50,000 divided into 25,000,000 ordinary shares of par value of $0.002 each, comprising 12,141,093 Class A ordinary shares of par value of $0.002 each, 2,858,908 Class B ordinary shares of par value of $0.002 each, and 9,999,999 shares of a par value of $0.002 each of such class or classes as the board of directors of the Company may determine in accordance with the Company's New M&A. to amend the Company's memorandum and articles of association currently in effect by the adoption of a new memorandum and articles of association to reflect the Share Consolidation; and to approve the appointment of MaloneBailey as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The Share Consolidation will be effective from 5 P.M. on October 29, 2024, Eastern time.
|
TZOO | Hot Stocks08:22 EDT Travelzoo sees Q4 revenue up - The company said, "For Q4, we expect growth in revenue year-over-year, albeit at a smaller pace than in 2023. However, there could be unexpected fluctuations. We also expect for Q4 higher profitability year-over-year and quarter-over-quarter. For 2025, we expect substantial growth in revenue as a result of additional revenue from membership fees. In December 2023, we announced the introduction of a membership fee for Travelzoo beginning January 1. We recognize membership fee revenue ratably over the subscription period. Legacy Travelzoo members as of December 31, 2023, which represent more than 95% of members, are exempt from the fee during 2024. Therefore, we do not anticipate membership fee revenue from these members before 2025.
|
LFMD | Hot Stocks08:21 EDT LifeMD launches TestoRx, direct to consumer testosterone replacement therapy - LifeMD announces the launch by its Rex MD men's health brand of TestoRx, a new direct-to-consumer men's hormone therapy telehealth offering. TestoRx offers an initial consultation with requisite blood tests to pre-screen patients, with treatment options that include both replacement therapy and alternative treatments to enhance endogenous hormone production - alongside ongoing telehealth visits and follow-up care.
|
JSPR | Hot Stocks08:21 EDT Jasper Therapeutics commences open-label extension study of chronic urticarias - Jasper Therapeutics announced that it is commencing an open-label extension study in chronic urticarias that will roll over patients from the BEACON and SPOTLIGHT studies upon completion of their initial follow up period. Additionally, Jasper also announced it has obtained regulatory clearance in the US and in the EU to further expand the BEACON study in CSU by adding a 360mg single-dose cohort (n=4), and that enrollment in this cohort has commenced. Jasper continues to plan to report initial data from all doses of the BEACON study up through 240mg in CSU during the week of January 6th, 2025. Data from the newly added 360mg single-dose cohort is expected to be reported in the first half of 2025.
|
TOI | Hot Stocks08:19 EDT The Oncology Institute joins Lantern's cancer care network of excellence - The Oncology Institute has joined Lantern's leading specialty care platform. Now, Lantern members will have access to cancer care at any of The Oncology Institute's state-of-the-art community clinics across 5 states. "At TOI, we believe that every cancer patient deserves access to the most advanced care in their community," said Dr. Dan Virnich, Chief Executive Officer of TOI. "We are excited to be part of Lantern's network, offering a new cancer care option for employers that prioritizes optimal outcomes, patient satisfaction, and reduces the financial burden often associated with cancer treatment, all in alignment with our mission and the needs of the community."
|
PMVP MRK | Hot Stocks08:18 EDT PMV provides update on Phase 2, Phase 1b portions of PYNNACLE trial - PMV Pharmaceuticals (PMVP) provided an update on the Phase 2 monotherapy and Phase 1b combination portions of the ongoing PYNNACLE clinical trial. Enrollment on track in registrational Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt; more than 75% of sites activated across the U.S., Europe, and Asia-Pacific; interim analysis expected by mid-2025. Dose-limiting toxicities observed in rezatapopt and Merck's (MRK) anti-PD-1 therapy KEYTRUDA combination arm of Phase 1b PYNNACLE trial; rezatapopt 500 mg once-daily in combination with pembrolizumab 200 mg every three weeks established as maximum tolerated dose; due to limited clinical benefit at this dose, PMV is discontinuing enrollment in the Phase 1b combination arm. PMV Pharmaceuticals is collaborating with MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center to support an investigator-initiated Phase 1b study evaluating rezatapopt monotherapy and in combination with azacitidine in patients with recurrent or refractory AML/MDS harboring a TP53 Y220C mutation
|
GAUZ RACE | Hot Stocks08:16 EDT Gauzy selected by Ferrari to become a strategic supplier - Gauzy (GAUZ) announced that Ferrari (RACE) has selected the Company to become a strategic supplier, resulting in Gauzy already beginning to serially produce its Suspended Particle Device Smart Glass technology for the car manufacturer's SUV. Gauzy's SPD light control glass is available in the panoramic roof of the SUV, marking the first-time Ferrari has implemented smart glass technology on a mass production level for any of its automotive designs
|
GAUZ | Hot Stocks08:14 EDT Gauzy selected by Ferrari to become a strategic supplier - Gauzy announced that Ferrari has selected the Company to become a strategic supplier, resulting in Gauzy already beginning to serially produce its Suspended Particle Device Smart Glass technology for the car manufacturer's SUV. Gauzy's SPD light control glass is available in the panoramic roof of the SUV, marking the first-time Ferrari has implemented smart glass technology on a mass production level for any of its automotive designs.
|
PHRRF | Hot Stocks08:13 EDT PharmaTher receives CRL from FDA for ketamine ANDA - PharmaTher Holdings announced that the U.S. Food and Drug Administration has issued a complete response letter, dated October 22, 2024, for the ketamine Abbreviated New Drug Application, which was assigned a Generic Drug User Fee Amendments of 2022 goal date of October 29, 2024. The deficiencies cited in the CRL are classified as MINOR. The FDA requested new and updated information and clarifications related to drug substance, drug product, manufacturing, and microbiology. The FDA did not express concern about the stability of the ketamine submission batches, which achieved 18 months of stability without issue, and no new preclinical and clinical studies were requested. As noted by the FDA in the CRL, the resubmission to this CRL will be considered to represent a MINOR AMENDMENT, given that the deficiencies have been classified as MINOR. The Company will be working with its third-party manufacturing partner to resolve these deficiencies and respond to the FDA in a timely fashion. The Company will provide a timeline for responding to the FDA as soon as possible and continue to provide updates as they occur.
|
ABOS | Hot Stocks08:13 EDT Acumen to deliver late-breaking presentation on ACU193 at CTAD conference - Acumen Pharmaceuticals announced that it will present a late-breaking presentation featuring insights from its participant screening approach used in the ongoing Phase 2 ALTITUDE-AD clinical trial evaluating sabirnetug, ACU193, at the 17th Annual Clinical Trials on Alzheimer's Disease, CTAD, conference taking place in Madrid, Spain, and online from Oct. 29 - Nov., 1, 2024. Acumen will provide updated data on how it uses a validated research-use plasma pTau217 assay to screen potential participants in ALTITUDE-AD. Phosphorylated tau at position 217 is a biomarker that indicates AD pathology. The plasma pTau217 assay is being used as an initial screening tool to identify people who qualify for additional amyloid testing to determine eligibility for the ALTITUDE-AD trial.
|
FRSH | Hot Stocks08:12 EDT Freshworks announces Freddy AI Agent - Freshworks announced Freddy AI Agent - a new generation of easy-to-deploy and use autonomous service agents. The company said, "Built to deliver exceptional customer experiences and employee experiences, Freddy AI Agent can be deployed in minutes and has helped users in customer support and IT autonomously resolve an average of 45% and 40% of service requests, respectively."
|
FOUR | Hot Stocks08:11 EDT Shift4 Payments and MSE in new, multi-year partnership for Capital One Arena - Monumental Sports & Entertainment or MSE has announced a new, multi-year partnership with Shift4, the leader in integrated payments & commerce technology, to handle payment processing for Capital One Arena, the multi-purpose sports and entertainment venue owned and operated by MSE in Washington, D.C. Shift4 will deliver the most comprehensive, end-to-end solution to connect all revenue centers across Capital One Arena, including Shift4's state-of-the-art payment processing technology to modernize the venue's transaction experience. The partnership will connect traditional point-of-sale and kiosk ordering with mobile and contactless solutions, so fans can efficiently order food and beverages and not miss extra minutes of the action. Shift4 will also process payments for ticket sales at the venue, including Washington Wizards and Washington Capitals games as well as hundreds of other events hosted at the arena each year...Shift4's integrated commerce solutions are used by every major professional sports league as well as colleges, entertainment venues, and many other business verticals, transforming the way fans and guests shop, order and pay.
|
WKSP | Hot Stocks08:11 EDT Worksport announces targeted market release of AL4 Premium Tonneau Cover - Workspor announces a targeted market release of its anticipated AL4 Premium Tonneau Cover on December 15th, 2024. The Company has already begun manufacturing production-ready samples for testing and customer evaluation. Engineering staff at the Company's state-of-the-art factory are finalizing the custom production lines required to produce large volumes of the new AL4 tonneau cover. The Company believes this launch will boost sales channels, improve profit margins, and enhance brand penetration.
|
HUMA | Hot Stocks08:10 EDT Humacyte to host KOL event on he use of ATEV for AV access in hemodialysis - Humacyte will host a virtual KOL event on Thursday, October 31, 2024 at 8:00 AM ET. To register, click here. The event will feature Charles Keith Ozaki, MD, Mohamad Anas Hussain, MD, PhD, and Timmy Lee, MD, MSPH, who will discuss the current treatment landscape and unmet need for improved arteriovenous access in hemodialysis patients. During the event, the surgeons will share case studies and highlight the V007 Phase 3 clinical results for Humacyte's acellular tissue engineered vessel product candidate versus arteriovenous fistula, for hemodialysis access in patients with end-stage kidney disease. The ATEV is an investigational, first-in-class bioengineered human tissue that is designed to be a universally implantable vascular conduit for use in arterial replacement and repair and dialysis access. The ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
|
GANX | Hot Stocks08:10 EDT Gain Therapeutics presents data at 36th ENA symposium - Gain Therapeutics announced the presentation of a poster at the 36th EORTC-NCI-AACR, ENA, Symposium on molecular targets and cancer therapeutics that details the use of the Company's Magellan drug discovery platform to identify allosteric inhibitors targeting discoidin domain receptor 2, DDR2. ENA 2024 is being held October 23-25 in Barcelona, Spain. The poster, "Identification of allosteric inhibitors targeting Discoidin Domain Receptor 2," which was presented on-site on October 23, detailed how the 3D structure of DDR2 guided a high-throughput virtual screening and subsequent experimental validation that resulted in GT-03842 and additional analogue compounds.
|
ANGO | Hot Stocks08:08 EDT AngioDynamics and UCLH launch study of 'long term effects' of NanoKnife System - AngioDynamics announced the launch of an international multi-center prospective registry study to assess the long term effects of treating men with unifocal intermediate-risk prostate cancer with the NanoKnife System in partnership with the University College London Hospital UCLH. Approximately 40% of all diagnosed prostate cancer cases are classified as intermediate risk.1 In the first year after surgery, 36% of men report urinary leakage, and 95% are affected by erectile dysfunction 70% described as moderate/severe The NanoKnife System delivers an innovative alternative to conventional radical surgery or radiotherapy, each of which often results in significant dysfunction in urinary continence and erectile potency. With its non-thermal approach, the NanoKnife system is engineered to preserve vital structures inside and outside the prostate, offering patients effective treatment of tumors, low complication rates, and minimal impact on quality of life.3
|
AUID | Hot Stocks08:08 EDT authID launches biometric identity services with Imperial Technologies - authID announced Imperial Technologies has signed a multi-year agreement and launched authID's biometric identity and document verification services to streamline and secure new customer onboarding. "This customer win and our expansion into the telecommunications vertical demonstrates our broad product fit and our strong ability to ensure enterprises 'Know Who's Behind the Device' during onboarding and throughout the user journey to prevent cybercriminals using malicious AI from impersonating users, deploying deepfakes, or performing account takeovers," said Rhon Daguro, CEO of authID. "authID is committed to helping Imperial Technologies enjoy the highest levels of identity trust delivered with market-leading speed, accuracy, and frictionless identity experiences that deepen customer loyalty."
|
LUMO | Hot Stocks08:08 EDT Lumos Pharma reports Q3 net loss $7.5M - Operating expenses for the third quarter ended September 30, 2024, were $8.4 million. Net loss for Q3 2024 was $7.5 million. Cash balance as of September 30, 2024, was $13.5 million. The Company is not providing any guidance at this time and withdraws its prior cash runway guidance.
|
IRON FGEN | Hot Stocks08:07 EDT Disc Medicine appoints Kaushik as Chief Technical Officer - Disc Medicine (IRON) announced the appointment of Rahul Rajan Kaushik, Ph.D. as the company's Chief Technical Officer. Kaushik most recently served on the executive team at FibroGen (FGEN) as Senior Vice President of Technical Operations.
|
RIO | Hot Stocks08:07 EDT Skyharbour completes majority earn-in, forms joint venture with Rio Tinto - Skyharbour Resources completed its earn-in requirements to earn a 51% interest in the Russell Lake Uranium Project, located in Northern Saskatchewan, Canada, pursuant to the option agreement dated May 10th, 2022, as amended on January 15, 2024 with Rio Tinto Exploration Canada. The Project is strategically located in the central core of the Eastern Athabasca Basin of northern Saskatchewan adjacent to regional infrastructure, including an all-weather road and powerline. Skyharbour will also be commencing an upcoming fall drill program which will consist of approximately 4,000-5,000m at the project. Formation of the JV: Pursuant to the Agreement, Skyharbour has now earned a 51% interest in the Property by initially paying a cash payment of CAD $508,200, issuing 3,584,014 common shares of the Company to Rio Tinto and incurring an aggregate $5,717,250 in exploration expenditures on the Property over the 3-year term of the earn-in. The Company and Rio Tinto have formed a joint venture to further explore the Property, with the Company holding a 51% ownership interest and Rio Tinto holding a 49% ownership interest. Russell Lake Uranium Project Overview: The Russell Lake Project is a large, advanced-stage uranium exploration property totalling 73,294 hectares strategically located between Cameco's Key Lake and McArthur River Projects and adjoining Denison's Wheeler River Project to the west and Skyharbour's Moore Uranium Project to the east. The northern extension of Highway 914 between Key Lake and McArthur River runs through the western extent of the Property and greatly enhances accessibility, while a high-voltage powerline is situated alongside this road and the western edge of the property south of Key Lake. Skyharbour's acquisition of a majority interest in Russell Lake creates a large, nearly contiguous block of highly prospective uranium claims totalling 108,999 hectares between the Russell Lake and the Moore uranium projects. Skyharbour now has a 51% interest in Russell Lake having formed a joint venture partnership with Rio Tinto at the project. There has been historical exploration carried out at Russell Lake, however most of it was conducted before 2010 prior to the discovery of several major deposits in/around the Athabasca Basin. In 2023, Skyharbour's inaugural diamond drilling program tested several Fox Lake Trail targets and the Grayling Zone. Significant uranium mineralization was intersected in the majority of holes at the Grayling Zone over a strike length exceeding one kilometre. Drill hole RSL23-01 intersected one of the better drill results from the project, returning a 5.9 metre wide intercept of 0.151% U3O8 at a depth of 338.4 metres, which included 1.0 metres of 0.366% U3O8 at 343.3 metres depth within a thrust wedge. More recently, Skyharbour completed 5,152 metres of drilling in a 2024 winter drill program earlier this year, making a new discovery at the newly identified Fork Target area. Hole RSL24-02 marks the best intercept of uranium mineralization historically at the project, returning a 2.5 metre wide intercept of 0.721% U3O8 at a relatively shallow depth of 338.1 metres, including 2.99% U3O8 over 0.5 metres at 339.6 metres just above the unconformity in the sandstone. Skyharbour is fully-funded for an upcoming fall drill program which will consist of approximately 4,000-5,000m at the project to follow up on the recent discovery. Several notable exploration targets exist on the property including the Grayling Zone, the M-Zone Extension target, the Little Man Lake target, the Christie Lake target, the Fox Lake Trail target and the newly identified Fork Zone target. More than 35 kilometres of largely untested prospective conductors in areas of low magnetic intensity also exist on the Property.
|
FYBR VZ | Hot Stocks08:07 EDT Glendon Capital opposes Frontier Communications' proposed sale to Verizon - Glendon Capital Management, a private investment firm which is one of the largest shareholders of Frontier Communications Parent (FYBR), owning nearly 10% of the outstanding shares of the company's common stock, sent a letter to Frontier's Board of Directors regarding Glendon's decision to vote against the proposed acquisition of Frontier by Verizon Communications (VZ) at a price of $38.50 per share. In the letter, Glendon expressed its belief that Frontier's enterprise value is at least $26B today, 30% higher than the current $20B enterprise value ascribed from the Verizon Transaction, based on an analysis of the most recent and relevant comparable transactions as well as Frontier's expected future cash flows. Additionally, Glendon expressed its disappointment with the Board's illogical and rushed setting of the record date and special meeting of stockholders, and urged an extension of both dates to enable shareholders to fully understand the standalone case for Frontier. Reference Link
|
BWB | Hot Stocks08:06 EDT Bridgewater Banc gets regulatory okays for First Minnetonka City acquisition - Bridgewater Bancshares announced the receipt of all necessary regulatory approvals, including approval from the Federal Deposit Insurance Corporation and the Minnesota Department of Commerce, to complete Bridgewater Bank's previously announced acquisition of First Minnetonka City Bank. The acquisition is expected to close in the fourth quarter of 2024, subject to the satisfaction of customary closing conditions.
|
AVTR | Hot Stocks08:06 EDT Avantor expands partnership with NIBRT - Avantor announced an expanded partnership with the National Institute for Bioprocessing Research and Training. The new collaboration will focus on addressing urgent bottlenecks in biopharma manufacturing, particularly in downstream optimization for monoclonal antibodies (mAbs), by providing cutting-edge equipment and specialized training. Avantor will provide a full suite of leading aseptic fluid handling equipment, including Masterflex pump systems and supporting single-use systems. These advanced tools are designed to create realistic biopharmaceutical workflows in NIBRT's state-of-the-art training rooms, offering trainees the opportunity to gain hands-on experience with equipment that mirrors real-world industry settings.
|
JYD | Hot Stocks08:05 EDT Jayud Global Logistics announces acquisitions in California, Georgia - Jayud Global announced the acquisition of significant stakes in two key logistics facilities in California and a licensed customs brokerage firm in Georgia. These strategic investments are part of Jayud's ongoing efforts to expand its operational footprint in the United States and enhance its comprehensive suite of logistics services. Jayud has acquired a 20% stake in a 70,000 sq.ft. warehouse located in Rialto, California, and a 49% stake in a 50,000 sq.ft. warehouse located in Chino, California. These facilities are located in major logistics hubs in California, enhancing Jayud's capacity to manage and streamline supply chains in one of the U.S.'s busiest trade corridors.
|
LUMO | Hot Stocks08:04 EDT Lumos Pharma enters merger agreement with Double Point Ventures to go private - Lumos Pharma has entered into a definitive merger agreement, dated October 22, 2024 whereby Double Point Ventures will acquire 100% of Lumos Pharma's outstanding shares of common stock for $4.25 per share in cash, plus one non-transferable, unsecured Contingent Value Right per share payable on achievement of certain milestones. Following a thorough review of financing and strategic alternatives, Lumos Pharma's Board of Directors, with the assistance of the Board's legal and financial advisors, unanimously determined that the acquisition by DPV is in the best interests of all Lumos Pharma stockholders, has approved the Merger Agreement and related transactions, and unanimously recommends that Lumos Pharma's stockholders tender their shares in the Offer. The transaction is expected to close before the end of 2024, subject to certain closing conditions including the tender of Lumos Pharma common stock representing at least a majority of the total number of outstanding shares. Lumos Pharma officers, directors and shareholders holding approximately 17.7% of Lumos Pharma common stock have signed support agreements under which such parties have agreed to tender their shares in the Offer and support the merger transaction. In addition, Lumos Pharma announced that the Company and the Food and Drug Administration are aligned on the Company's final Phase 3 trial design which will consist of a global, multi-site, double-blinded, placebo-controlled trial with two cohorts randomized 2:1 to 1.6 mg/kg/day oral LUM-201 or daily placebo, each on treatment for 12 months. The single endpoint will be the comparison of LUM-201 annualized height velocity (AHV) to placebo AHV. The Company believes this trial design significantly reduces risk for its Phase 3 program. This trial will be conducted at approximately 80 global sites and is expected to be initiated in Q2 2025. The Merger Agreement is structured as a tender offer by a wholly owned subsidiary of DPV for 100% of the outstanding shares of common stock of Lumos Pharma for $4.25 per share in cash at closing and one CVR for each share of common stock outstanding, representing the future right to receive additional contingent cash payments upon the achievement of certain milestone events relating to the level of annual global net revenue of LUM-201 up to the year 2037, different transactions involving Lumos Pharma or its assets that occur within 18 months of closing or certain sales, license or similar revenue-generating agreements entered into within 18 months of closing and that are related to Lumos Pharma's legacy products other than LUM-201. There can be no assurance any payments will be made with respect to the CVRs. The purchase price of $4.25 per share represents a total equity value of approximately $38 million, a premium of 7.6% to Lumos Pharma's closing share price of $3.95 on October 22, 2024, and a premium of 10.5% to Lumos Pharma's 30-trading-day volume weighted average price as of October 22, 2024. The transactions contemplated by the Merger Agreement are not subject to any financing condition and DPV will fund the transactions from its existing cash resources. Upon completion of the Merger, Lumos Pharma will continue as an indirect wholly-owned subsidiary of DPV, and operate as a standalone business of DPV, from Lumos Pharma headquarters in Austin, Texas. In light of the Offer, Lumos Pharma will not host a third quarter 2024 financial results call. The Company will file a Quarterly Report on Form 10-Q for the period ended September 30, 2024, in the ordinary course as required by Securities and Exchange Commission rules.
|
PYPL GPN | Hot Stocks08:02 EDT PayPal and Global Payments expand collaboration - PayPal Holdings (PYPL) announced an expanded collaboration with Global Payments (GPN) aimed at transforming checkout experiences. This partnership will see Global Payments offer their U.S. merchants enhanced PayPal and Venmo branded checkout solutions and accelerated guest checkout through Fastlane by PayPal. Fastlane enhances the shopping experience for consumers and drives increased conversion rates for businesses leveraging the platform. Fastlane harnesses PayPal's decades of payment expertise to revolutionize the guest checkout experience, enabling users to complete purchases in as little as one click. This innovative solution empowers guest shoppers and can help deliver nearly 50% higher checkout conversion rates compared to traditional guest checkout flows for consumers paying with a card, while reducing checkout time by more than 28%*.
|
DGX | Hot Stocks07:54 EDT Quest Diagnostics awarded several contracts by CDC - Quest Diagnostics announced that it has been awarded several contracts by the U.S. Centers for Disease Control and Prevention, or CDC, to support testing and sustained laboratory readiness for two emerging infectious diseases recently identified in people in the Americas. The agreements will support the nation's preparedness for avian influenza and Oropouche viruses by ensuring a national commercial laboratory provider is able to quickly supplement public health laboratories in the event there is an infectious diseases outbreak in people. The contracts also provide funding to enable the company to maintain testing readiness, such as for adequate supplies of certain equipment and chemical reagents used to perform the tests, on a sustained basis. Quest will introduce an immediate response molecular laboratory test to aid in the detection of avian influenza A H5 virus. The new multi-target molecular diagnostic test is intended for use in people suspected of being infected with influenza A H5 virus. The test will be available with a prescription from a provider for clinical purposes at the end of the month.i Quest's advanced laboratory in San Juan Capistrano, California, developed and will perform the test. CDC has also awarded Quest a contract to develop diagnostics to aid the detection of Oropouche virus, an emerging virus in the Americas that is spread to people by infected biting midges and some mosquito species.
|
NEP | Hot Stocks07:46 EDT NextEra Energy Partners reaffirms FY24 portfolio contribution expectations - The company said, "NextEra Energy Partners continues to expect the run-rate contribution for adjusted EBITDA from its forecasted portfolio at December 31, to be in the range of $1.9B-$2.1B. The year-end 2024 run-rate projection reflects expected calendar-year 2025 contributions from the forecasted portfolio at year-end 2024. The partnership also continues to evaluate alternatives to address its remaining convertible equity portfolio financing obligations and its cost of capital, focusing on its capital structure and the potential for redeployment of more cash flow toward driving organic cash flow growth. Given the demand for power, NextEra Energy Partners has many ways in which it can seek to grow, which could include not only acquiring assets, but also wind repowerings and potentially other organic growth opportunities. NextEra Energy Partners plans to complete its review by no later than the Q4 call and intends to provide its distribution and run-rate cash available for distribution expectations at that time."
|
RDW BMY | Hot Stocks07:44 EDT Redwire launches investigation to ISS with BMS to study drugs with PIL-BOX - Redwire Corporation (RDW) announced that it is launching an investigation to the International Space Station ISS in partnership with global leading biopharmaceutical company Bristol Myers Squibb (BMY) BMS to study model small molecule compounds using Redwire's pharmaceutical drug development platform PIL-BOX . The research being conducted with BMS has the potential to enhance drug stability, streamline manufacturing processes, and improve efficiencies across various therapeutic areas, including oncology, immunology, and cardiovascular disease. Additionally, Redwire will be launching a PIL-BOX investigation in partnership with pharmaceutical startup company ExesaLibero Pharma to study the novel drug ELP-004, which prevents excess bone removal associated with numerous diseases, including rheumatoid arthritis, multiple myeloma, and breast and prostate cancers. These newest spaceflight investigations further establish PIL-BOX as the premier space pharmaceutical research platform with 16 PIL-BOXes flown to date and 12 more set to launch on the next commercial resupply mission to the ISS. "We are grateful for our partnership with Bristol Myers Squibb and ExesaLibero Pharma, along with the support from NASA and the ISS National Lab, as we continue to operate Redwire's PIL-BOX platform for reliably manufacturing pharmaceutical crystals in space," said John Vellinger, President of In-Space Industries at Redwire. "These newest investigations, coupled with the success of previous PIL-BOX investigations over the past year, are enabling us to leverage the microgravity environment to conduct cutting-edge research to improve human health on Earth."
|
KURA | Hot Stocks07:41 EDT Kura Oncology presents new data on KO-2806 with targeted therapies - Kura Oncology announced the upcoming presentation of new preclinical data supporting the combination of its next-generation farnesyl transferase inhibitor, FTI, KO-2806 with targeted therapies, including KRASG12C inhibitors and pan-RAS inhibitors, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. "We look forward to presenting an update to our growing body of preclinical and clinical data that demonstrate the potential of KO-2806 as a companion therapeutic to augment the antitumor activities of KRASG12C and pan-RAS inhibitors," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.
|
AMST | Hot Stocks07:40 EDT Amesite announces customization for paid NurseMagic enterprise licensees - Amesite announced the company's app, NurseMagic, enables multiple professions to use the app with customized features for each. Enterprises can now deliver tailored features to employees across different professions using a single solution, with a paid subscription. Enterprise employees currently using NurseMagic range from CEOs and other executives to clinical officers, CNSs, NPs, RNs, Pediatric RNs, PTs, OTs, LVNs/LPNs, CNAs, NAs, Home Care Nurses, HHAs and caregivers. These professions collectively represent 13M individuals in the United States. Amesite is presently piloting the enterprise tool with long-term care companies. Long term care markets are enormous, spanning skilled nursing, home health care, assisted living, hospice & palliative care and others, comprising over $490 billion in value. Amesite's recently released Home Health Care Outlook Report details some of the biggest market pains in the industry. Turnover, for example, is both rampant and expensive, with 80% of employees leaving within their first 100 days on staff, costing an agency with 100 workers over $420,000 per year in replacement costs alone. Over 700,000 job openings for home health and personal care aides are anticipated each year over the next decade.
|
ZENA | Hot Stocks07:40 EDT ZenaTech announces agreement to acquire ZooOffice - ZenaTech announced that it has entered into an agreement to acquire ZooOffice, the holding company for software companies Jadian and DeskFlex, from ZenaTech's former parent company. The acquisition of these two software companies will provide important compliance and inspection software as well as scheduling and mapping software that will be incorporated into ZenaTech's ZenaDrone AI drone solutions. This transaction further expands ZenaTech's portfolio of SaaS software solutions and customer base and is expected to add to recurring revenue in the government sector among others. The acquisition is subject to shareholder and regulatory approvals that may be required.
|
TRP | Hot Stocks07:39 EDT TC Energy provides results of Series 9 Shares conversion elections - TC Energy announced that 1,297,203 of its 18,000,000 fixed rate Cumulative Redeemable First Preferred Shares, Series 9 have been elected for conversion on a one-for-one basis into floating rate Cumulative Redeemable First Preferred Shares, Series 10 effective on Oct. 30, 2024. As a result, on Oct. 30, 2024, TC Energy will have 16,702,797 Series 9 Shares and 1,297,203 Series 10 Shares issued and outstanding. The Series 9 Shares and Series 10 Shares will be listed on the Toronto Stock Exchange under the symbols TRP.PR.E and TRP.PR.L, respectively.
|
BA | Hot Stocks07:38 EDT Boeing CEO says company 'clearly at a crossroads' - In prepared remarks ahead of the company's Q3 earnings conference call, Boeing President and CEO Kelly Ortberg said "Clearly, we are at a crossroads. The trust in our company has eroded. We're saddled with too much debt. We've had serious lapses in our performance across the company which have disappointed many of our customers." Ortberg sees opportunities ahead, including that Boeing's backlog is roughly half-a-trillion dollars, its customer base "want us and need us to succeed," and its employees "are thirsty to get back to the iconic company they know." Ortberg says Boeing needs a fundamental culture change, must stabilize the business, needs to improve execution discipline on new platform commitments, and must build a new future for Boeing. Ortberg says he is encouraged with the progress Boeing is making already.
|
STRM | Hot Stocks07:36 EDT Streamline Health expands relationship with existing eValuator client - Streamline Health Solutions has expanded its relationship with an existing eValuator client include the recently released eValuator Quality Module. Streamline expects that this module will increase the SaaS revenues from its eValuator relationship with this client by 25%.
|
LILM GE | Hot Stocks07:36 EDT Lilium, GE Aerospace partner for eVTOL flght safety - With eVTOLs on the cusp of taking off commercially in the coming years, GE Aerospace (GE) is partnering with Lilium (LILM), to build a solid safety foundation for this exciting new mode of travel. The two companies are bringing together their respective flight data and analytics platforms to build scalable flight data management solutions that inform the right safety standards and guidelines for eVTOL operators. GE's Event Measurement System platform will be a critical digital component of Lilium's unique and comprehensive aftermarket offering "POWER-ON" that provides safe, efficient, and customer-centric solutions for operators of the Lilium Jet. All Lilium customers will have access to a range of digital services to support their daily operations with critical insights and actionable data. As part of this extraordinary partnership, GE Aerospace and Lilium will build an OEM-level Flight Data Monitoring or Flight Operations Quality Assurance program, to monitor eVTOL safety at a fleet wide level, as well as establish a voluntary FDM program option for Lilium's customers, built in collaboration by both companies
|
VRAX | Hot Stocks07:34 EDT Virax Biolabs announces distribution agreement with Europa Biosite - Virax Biolabs announced that it has entered into a distribution agreement with Europa Biosite to commercialize the company's ImmuneSelect Research Use portfolio in the United Kingdom and Ireland through its wholly owned subsidiary Cambridge Bioscience.
|
BA | Hot Stocks07:33 EDT Boeing: Q3 results reflect IAM work stoppage, previously announced charges - Q3 financials reflect impacts of the International Association of Machinists and Aerospace Workers work stoppage and previously announced charges on commercial and defense programs.
|
FOMNF | Hot Stocks07:31 EDT Forte Minerals to acquire Miscanthus epithermal gold, porphyry copper prospects - Forte Minerals has finalized the acquisition of the Miscanthus high sulphidation epithermal gold-Ag and porphyry copper-molybdenum-gold prospects from its strategic partner Globetrotters Resource Group. Key details include: Property Details: Miscanthus consists of 4 concessions totaling 3,200 hectares. Previous Ownership: Initially acquired by Globetrotters in 2022 from Sumitomo Metal Mining Peru. Transfer: The concessions are to be transferred to Forte's Peruvian subsidiary, Cordillera Resources Peru. Acquisition Terms under the Mineral Asset Purchase Agreement dated October 21, 2024 between the Company and Globetrotters: One-time cash payment of $27,000.00; Issuance of 3,000,000 common shares of Forte at deemed price of $0.23 per share. 1.0% net smelter return royalty interest on the concessions to Globetrotters. Environmental Approval: Miscanthus has an approved DIA environmental drilling permit, allowing for up to 40 platforms of drilling over 172 hectares, significantly reducing permitting risk. Property Highlights: Location: Approximately 390 km southeast of Lima at 4,100 meters elevation. Access: Via a network of paved and gravel roads, 60 km inland from Nazca. Proximity to Infrastructure: 120 km from Marcona port and near the Mantaro-Southern Peru power grid. Exploration Potential: Miscanthus is considered highly prospective, with the potential for the discovery of a large, telescoped porphyry Cu-Mo-Au system, overprinted by high-sulphidation epithermal Au-Ag mineralization.
|
BA | Hot Stocks07:31 EDT Boeing reports total company backlog of $511B, including over 5,400 airplanes
|
BA | Hot Stocks07:31 EDT Boeing reports Q3 operating cash flow of ($1.3B), free cash flow ($2B)
|
AZ | Hot Stocks07:28 EDT A2Z Cust2Mate announces compliance with Nasdaq listing requirements - A2Z Cust2Mate Solutions has received formal notice from the Nasdaq Stock Market stating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). As previously disclosed, the Company received a written notice from Nasdaq on April 24, 2024, notifying the Company that it had failed to meet the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market. To regain compliance with the Listing Rule, the Company's common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on October 21, 2024. Nasdaq has stated that this matter is now closed. A2Z further announced that, the board of directors has approved the extension of the expiry dates of a total of 653,746 share purchase warrants, by twelve months to Nov 6, 2025. The Warrants were issued pursuant to private placements which closed on November 8, 2022. Each Warrant entitles the holder thereof to acquire one common share of the Company at a price of $3.75 per common share, and all other terms of the Warrants, including exercise price, will remain the same.
|
VEV | Hot Stocks07:26 EDT Vicinity Motor receives Nasdaq delisting notice - Vicinity Motor has received a letter from the Nasdaq Listing Qualifications Department notifying the Company of its failure to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The letter stated that as of October 21, 2024, the Company's stock had not regained compliance, as its shares continued to trade below $1. Additionally, the Company received a separate delisting determination based on its recent entry into receivership pursuant to the Order of the Supreme Court of British Columbia. In light of the receivership filing, Nasdaq has determined that delisting is also warranted under Listing Rules 5101, 5110(b), and IM-5101-1. The Company will not appeal the decision, and trading of its common shares will be suspended at the opening of business on October 31, 2024, with a Form 25-NSE filed with the Securities and Exchange Commission, removing Vicinity Motor Corp. from the Nasdaq Capital Market.
|
DEC | Hot Stocks07:24 EDT Diversified Energy announces natural gas supply contract with LNG facility - Diversified Energy Company announced the execution of a supply agreement with a major Gulf Coast LNG facility to provide natural gas to export. Under the terms of the agreement, Diversified will provide approximately 40 Bcf of natural gas under a fixed pricing construct indexed to Gulf Coast pricing for a period of three years, beginning in November 2024. Fueled by a vision to supply clean American energy to the world, this significant contract collaboration encompasses the commitment to ensure energy security for global trading partners who are facing supply disruptions, geopolitical tensions, rising regional demands, and changing consumption patterns. Additionally, the Company has been able to strategically take advantage of the recent strength of the natural gas price curve to add to its multiple-year hedge portfolio in 2025 through 2027, with an average NYMEX hedge price of approximately $3.45 per MMBtu. The Company will provide additional disclosures and an updated hedging schedule with its Third Quarter 2024 Trading Statement.
|
BCYC | Hot Stocks07:24 EDT Bicycle Therapeutics announces presentation of MT1-MMP data - Bicycle Therapeutics announced the presentation of the first human imaging data validating the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrating the positive properties of Bicycle Radionuclide Conjugates for radiopharmaceutical use, as well as preclinical data demonstrating optimized BRC radioisotope delivery at the European Association of Nuclear Medicine, or EANM, 2024 Congress in Hamburg, Germany. In line with Bicycle Therapeutics' radiopharmaceuticals strategy, the company selected tumor antigen EphA2 as its second BRC target and signed a letter of intent with isotope technology company Eckert & Ziegler to put in place an agreement to supply a range of radioisotopes and develop and manufacture BRC molecules. In an e-poster, Bicycle Therapeutics presented preclinical data demonstrating the suitability of Bicycle molecules to deliver indium to tumors in vivo due to their properties, including specific tumor uptake, rapid tumor penetration and rapid renal elimination. Additionally, imaging showed how the biodistribution profile of BRCs can be optimized to maintain high tumor uptake and retention while significantly reducing kidney uptake and retention. These data build on the body of preclinical data the company has published in this area demonstrating the use of Bicycle molecules to effectively deliver various radioisotopes, such as lutetium and lead, to tumors. Altogether, the data presented at EANM validate the potential of MT1-MMP as a novel target in the treatment of cancer, demonstrate the translatability of BRC preclinical data and highlight the potential of Bicycle molecules for targeted radionuclide therapy.
|
JZ | Hot Stocks07:23 EDT Jianzhi Education strengthens edtech capabilities with new AI initiatives - Jianzhi Education Technology Group announced its new Artificial Intelligence, AI, initiatives. Jianzhi will develop and implement new algorithms to facilitate educational content and utilize AI in various aspects of the teaching process, including teaching design, student performance analysis, and homework grading, with a view to significantly enhance teaching efficiency and students' learning experience.
|
KYMR | Hot Stocks07:22 EDT Kymera Therapeutics announces three presentations at EOTC-NI-AACR - Kymera Therapeutics announced that new preclinical data from its innovative TPD platform will be presented across three poster presentations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024, in Barcelona, Spain. The presentations include new data on its preclinical biomarker-based approach for KT-253, its MDM2 degrader. New data highlights the Company's research efforts to identify patient populations sensitive to the KT-253 degrader mechanism and define biomarkers associated with an acute apoptotic response in tumors. Using an innovative machine learning framework to develop a predictive signature, the results identified tumor types sensitive to KT-253 that are consistent with preclinical and early clinical findings, including acute myeloid leukemia, neuroendocrine tumors, and subsets of solid tumors with or without neuroendocrine features
|
REFI | Hot Stocks07:21 EDT Chicago Atlantic closes on $50M unsecured term loan - Chicago Atlantic Real Estate Finance entered into a $50.0 million unsecured term loan from two institutional private lending platforms to fund the Company's future investments and other general corporate purposes. The unsecured term loan matures in October 2028, is interest only and bears a fixed cash interest rate of 9.0%. The Company can prepay the term loan in whole or in part at any time and from time to time subject to applicable prepayment penalties. The full balance of the loan was drawn at closing and was used to repay current outstanding borrowings on the Company's $110.0 million senior secured revolving credit facility and for other working capital purposes. The Company also announced that Egan-Jones has assigned a rating of BBB+ to both the Company and the senior unsecured term loan.
|
CATX | Hot Stocks07:21 EDT Perspective Therapeutics presents updates at 37th Annual Congress of EANM - Perspective Therapeutics announced six updates on the Company's radiopharmaceutical programs being presented at the 37th Annual Congress of the European Association of Nuclear Medicine, EANM, held in Hamburg, Germany, from October 19-23, 2024. "The preclinical studies and first-in-human imaging data presented with (212Pb)Pb-PSV359, our novel cyclic peptide targeting fibroblast activation protein-alpha, are very encouraging and validate the potential of this radiopharmaceutical in treating a variety of epithelial-derived cancers," said Thijs Spoor, Perspective's CEO. "We also note the valuable contributions from our scientists, collaborators and independent investigators to advancing the development of our potential new medicines, including updated safety and efficacy observations of (212Pb)Pb-VMT-alpha-NET."
|
GLUE | Hot Stocks07:19 EDT Monte Rosa Therapeutics presents preclinical data at ENA 2024 - Monte Rosa Therapeutics announced the company will present preclinical data at the 36th EORTC-NCI-AACR Symposium, ENA 2024, taking place in Barcelona, Spain from October 23 to 25, on the potential of its cyclin E1-directed molecular glue degraders for the treatment of CCNE1-amplified solid tumors. The data being presented demonstrate that Monte Rosa's MGD degrades cyclin E1 with a high level of selectivity, sparing other closely related proteins, including other cyclins, and cyclin-dependent kinases. The data also showed that a cyclin E1-directed MGD led to downstream pathway inhibition and induced tumor growth suppression and regression preferentially in CCNE1-amplified and over-expressing tumor cell lines and xenograft models. The Company continues to perform preclinical research in order to progress the program towards a development candidate nomination.
|
GNTA | Hot Stocks07:19 EDT Genenta Science CEO to present at U.S. Senate meeting - Genenta Science announced that Pierluigi Paracchi, CEO, will attend as a speaker to the Italy-U.S. meeting "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective" scheduled at 2.00 PM on October 25th, 2024 at the U.S. Senate - Washington, D.C. The event is organized by the U.S. National Security Commission on Emerging Biotechnology and the Italian Embassy in the U.S. The upcoming mission to Washington, D.C. is part of the strategic plan of the Italian Working Group on the Internationalization of the Biotech Sector established by the Deputy Prime Minister and Minister of Foreign Affairs Antonio Tajan. Pierluigi Paracchi stated: "With the pandemic, biotechnologies have been elevated to strategic technologies by leading global nations. Italy, with its rich scientific heritage, must ensure that these innovations are rapidly and concretely applied, while preserving them as national assets. At the same time, the internationalization of the sector, collaboration with partner countries, and the attraction of foreign investments are crucial for ensuring competitive growth. Government investment agencies should focus on strategic operations of a competitive scale, aligning with the international standards of countries already leading the sector."
|
AZN | Hot Stocks07:18 EDT Eccogene receives milestone payment of $60M from AstraZeneca - Eccogene will receive a $60 million payment from AstraZeneca, which is being triggered by successfully achieving milestones related to the development of ECC5004/AZD5004 including the first patient dosed in the Phase 2b program. VISTA and SOLSTICE are two global Phase 2b multicenter trials assessing the efficacy and safety of ECC5004/AZD5004, administered orally, once daily, to participants who are obese or overweight with at least one weight-related comorbidity and type 2 diabetes, respectively. AstraZeneca licensed the global rights to ECC5004/AZD5004 from Eccogene in November 2023, for which the Company received an upfront payment of $185 million and can receive up to $1.825 billion in future milestones, as well as royalty payments. Eccogene retains co-development and co-commercialization rights to ECC5004/AZD5004 in China.
|
ORIC | Hot Stocks07:17 EDT Oric Pharmaceuticals presents data on ORIC-114 - ORIC Pharmaceuticals announced the company presented a poster highlighting certain best-in-class properties of ORIC-114, a brain penetrant, orally bioavailable, irreversible EGFR/HER2 inhibitor, to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Key findings of this poster presentation: Demonstrates regressions in all EGFR mutant in vivo models tested, including cell-derived xenografts, patient-derived xenografts and intracranial models that encompass exon 20 insertion and atypical mutant models. An in vivo model with complex atypical mutant EGFR dosed with ORIC-114 notably shows 100% tumor regressions and all tumors experienced a complete response. In an expanded preclinical comparative analysis of exon 20 insertion, atypical PACC and other mutations, overall ORIC-114 is the most potent across EGFR mutational classes whilst displaying comparative wild-type selectivity in cell-based assays, relative to firmonertinib, zipalertinib, lazertinib and BDTX-1535. In head-to-head comparisons with firmonertinib, zipalertinib, lazertinib and BDTX-1535, ORIC-114 has superior kinome selectivity with no off-target kinase liabilities identified. Shows complete molecular responses in ctDNA from patients with EGFR exon 20 insertion and PACC mutations from Phase 1 dose escalation study.
|
COGT | Hot Stocks07:15 EDT Cogent Biosciences announces pipeline expansion into KRAS - Cogent Biosciences announced the addition of a potent and selective KRAS inhibitor to its pipeline. Preclinical data from this program as well as its newly announced H1047R mutant-selective PI3Kalpha clinical candidate will be presented in two poster presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics taking place in Barcelona, Spain October 23-25, 2024. Title: Identification of a Pan KRAS(On) Inhibitor with Selectivity Over KRAS over H/NRAS and pM Activity Across Prevalent KRAS Mutations: Mutations in KRAS are among the most prevalent mutations found in cancer, occurring most often in colorectal cancer, non-small cell lung cancer and pancreatic cancer. The poster presented today describes Cogent's internally-developed pan KRAS(ON) inhibitor with selectivity over HRAS and NRAS and picomolar activity across KRAS mutations without the potential liabilities of molecules in the class. Following oral administration, CGT6737 demonstrated robust PK/PD and tumor growth inhibition with 90% PD inhibition in mouse xenograft models. Lead optimization of CGT6737 is ongoing. Title: Preclinical Characterization of a Novel PI3Kalpha H1047R Mutant Selective Inhibitor: Cogent is also developing a potential best-in-class, wild-type-sparing, PI3Kalpha inhibitor that provides coverage for the H1047R mutation, which affects greater than55,000 cancer patients each year. The phosphoinositide 3-kinase pathway is a key cell cycle regulating pathway that has an established role in tumor growth and development. The approved agents for these patients often lead to dose limitations, resulting from activity against wild-type PI3Kalpha. The poster presented today highlights Cogent's clinical candidate CGT6297, a potent allosteric inhibitor of PI3K, with 25-fold selectivity over PI3Kalpha WT. CGT6297 has high oral bioavailability and low clearance across species, providing robust inhibition of downstream signaling and efficacy in animal models. Importantly, when compared to a clinically relevant dose of a currently approved therapy in a mouse tumor model, CGT6297 demonstrated superior efficacy with no increase in insulin. IND-enabling studies are expected to be initiated in 2025.
|
YUMC | Hot Stocks07:15 EDT Yum China to consider declaration and payment of a quarterly dividend - Yum China Holdings announced, in compliance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong, or HKEX, which require advance notice of board meetings at which a dividend is expected to be declared, that its board of directors will consider the declaration and payment of a quarterly dividend. If the Board decides to proceed, the declaration will be adopted by Board resolution on or around November 4 and will be promptly disclosed by the Company.
|
TSAT | Hot Stocks07:14 EDT Telesat awards contract to Intellian to design, supply gateway antennas - Telesat and Intellian announced a contract award for Intellian to design, supply, install, and integrate 127 Gateway Antenna Systems at Landing Stations for the Telesat Lightspeed Low Earth Orbit, LEO, constellation. Intellian's 4-meter Gateway Antenna System has been meticulously engineered to optimize tracking precision and high gain performance for LEO satellites and durability in all weather conditions. The Telesat Lightspeed Landing Stations play a crucial role in the delivery of Telesat's enterprise-class services.
|
AGIO | Hot Stocks07:13 EDT Agios Pharmaceuticals completes enrollment of Phase 3 RISE UP study - Agios Pharmaceuticals announced that enrollment is complete for the Phase 3 RISE UP study. This global, double-blind, randomized, placebo-controlled trial is evaluating the efficacy and safety of mitapivat, an oral, small molecule PK activator, in sickle cell disease patients who are 16 years of age or older. Agios expects to report topline results from this 52-week Phase 3 study in late 2025. The Phase 3 RISE UP study enrolled more than 200 patients worldwide. The trial's primary endpoints are hemoglobin response, defined as a greater than or equal to1.0 g/dL increase in average hemoglobin concentration from Week 24 through Week 52 compared with baseline, and annualized rate of sickle cell pain crises. These are important clinical endpoints in sickle cell disease because anemia and pain episodes are the hallmark symptoms of the disease that severely impact a patient's quality of life.
|
CLMB | Hot Stocks07:13 EDT Climb Global's Climb Channel launches NA partnership with FinQuery - Climb Channel Solutions, a wholly owned subsidiary of Climb Global Solutions, announced the addition of FinQuery to their North American, NA, line card. The strategic partnership with Climb Channel Solutions will expand the reach of FinQuery's Software Management platform, enabling them to assist a broader range of organizations in achieving significant cost savings, mitigating risk, and enhancing overall efficiency. "Climb is excited about the addition of FinQuery and their Software Management platform which offers total visibility into where companies spend most of their budget; leases, contacts, and software applications," said Dale Foster, CEO of Climb Channel Solutions.
|
OLMA | Hot Stocks07:12 EDT Olema Oncology presents preclinical data on anti-tumor activity for OP-3136 - Olema Pharmaceuticals announced results from three preclinical studies that will be presented during poster sessions at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. Title: "Combining OP-3136, a KAT6 inhibitor, with endocrine therapy and CDK4/6 inhibitor enhances anti-tumor activity in ER+/HER2- breast cancer models". Key findings include: OP-3136 inhibited cell proliferation and synergized with anti-estrogens and a CDK4/6 inhibitor in a breast cancer cell line. OP-3136 led to either tumor growth inhibition or tumor regression in vivo in xenograft models across all treatment groups. In combination with OP-3136, palazestrant was consistently superior to fulvestrant and led to improved anti-tumor activity and tumor regression. OP-3136 showed robust synergistic anti-tumor activity when combined with fulvestrant or palazestrant as doublet therapy in breast cancer models. Title: "Combining palazestrant, a CERAN, and everolimus, an mTOR inhibitor, enhances tumor suppression in ER+/HER2- breast cancer models": Key findings include: Palazestrant and everolimus demonstrate synergy in vitro and in vivo and resulted in greater anti-proliferative activity than either agent alone. Combining palazestrant with everolimus causes gene signature transcriptional changes, downregulating cell cycle progression and upregulating apoptosis. These data support clinical investigation of the combination of palazestrant and everolimus. Title: "Combining palazestrant, a CERAN, and capivasertib, a pan-AKT inhibitor, enhances tumor suppression in ER+/HER2- breast cancer models": Key findings include: Palazestrant and capivasertib work synergistically to inhibit proliferation of multiple ER+ breast cancer models, both in vitro and in vivo. Palazestrant demonstrates superior anti-tumor efficacy over fulvestrant in combination with capivasertib, significantly inhibiting and repressing tumor growth. Combining palazestrant and capivasertib increases downregulation of genes associated with cell cycle progression. These data support clinical investigation of the combination of palazestrant and capivasertib.
|
KXIN | Hot Stocks07:11 EDT Kaixin Auto announces 1-for-60 share consolidation - Kaixin announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-60, effective on October 25, 2024. The Company's ordinary shares are expected to begin trading on a post-consolidation basis at the open of the market session on October 25, 2024. Upon the market opening on October 25, 2024, the Company's ordinary shares will continue to be traded on The Nasdaq Capital Market under the symbol "KXIN" with the new CUSIP number G5223X159.
|
OKYO | Hot Stocks07:10 EDT Okyo Pharma announces first patient dosed in Phase 2 trial of OK-101 - OKYO Pharma announces that the first patient has been dosed in the Phase 2 trial of topical ocular OK-101 to treat NCP. The Phase 2 study is designed as a double-masked, randomized, 12-week placebo-controlled trial in NCP patients. A total of 48 patients are planned to enroll for the study, with NCP disease confirmed via confocal microscopy.
|
EYEN | Hot Stocks07:10 EDT Eyenovia announces publication of study on Optejet, presentation - Eyenovia announced a publication in the Journal of Ocular Pharmacology and Therapeutics as well as an upcoming presentation at the American Academy of Optometry's "Academy 2024 Indianapolis" Annual Meeting. The peer-reviewed paper highlights the ability of Eyenovia's proprietary Optejet dispenser to deliver a therapeutic dose of latanoprost with far less exposure to the preservative benzalkonium chloride than traditional eye drops. In contrast, this in-vitro study of latanoprost plus BAK delivered in the same amount by the Optejet dispenser avoided the cytotoxicity associated with larger volumes found in eye drops and was similar to no treatment controls and BAK-free latanoprost drops. Eyenovia also announced today an upcoming presentation at the American Academy of Optometry's "Academy 2024 Indianapolis," which is being held November 6-9, in Indianapolis, IN. The presentation details the results of an open-label Phase 4 study of 1% tropicamide and 2.5% phenylephrine ophthalmic metered spray, similar to Mydcombi, Eyenovia's commercially available product for inducing mydriasis.
|
MRK | Hot Stocks07:08 EDT Merck acquires Modifi Biosciences for $30M upfront - Modifi Biosciences announced that the company has been acquired by Merck. Under the terms of the agreement Merck, through a subsidiary, has acquired all outstanding shares of Modifi Biosciences for $30M upfront. Modifi Biosciences shareholders are also eligible to receive potential milestone payments totaling up to $1.3B. Modifi Biosciences, a Yale University spinout company formed in 2021, has developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase. Modifi Biosciences' research has been validated through its initial work published by the academic founders in Science in 2022, and subsequent compelling pre-clinical data across a number of tumor models including patient-derived xenograft models of gliomas and other cancers with intrinsic DNA repair defects.
|
RNAZ | Hot Stocks07:08 EDT Transcode announces SRC approval of second cohort in Phase 1 TTX-MC138 trial - TransCode Therapeutics announced that the Safety Review Committee, SRC, monitoring its Phase 1 clinical trial has unanimously approved opening of the second cohort of patients based on its favorable review of Cohort 1 safety data. The therapeutic candidate being evaluated, TTX-MC138, is TransCode's lead candidate designed to inhibit microRNA-10b, a microRNA critical to the emergence and progression of metastatic cancer. All patients in the first cohort remain on study for continued treatment. No significant safety or dose limiting toxicities have been reported. The dose administered to the second cohort will be approximately double the dose administered to the first cohort.
|
GD | Hot Stocks07:01 EDT General Dynamics reports company-wide backlog of $92.6B - The consolidated book-to-bill ratio, defined as orders divided by revenue, was 1.1-to-1 for the quarter. Company-wide backlog was $92.6B. Estimated potential contract value, representing management's estimate of additional value in unfunded indefinite delivery, indefinite quantity contracts and unexercised options, was $45B. Total estimated contract value, the sum of all backlog components, was $137.6B.
|
MAG | Hot Stocks06:51 EDT MAG Silver reports Q3 production from Juanicipio - Q3 highlights: Consistent throughput: The Juanicipio plant maintained steady production with 332,290 tonnes of ore processed in Q3, consistent with Q2, marking the third consecutive quarter of 100% ore processing through the Juanicipio plant. Continued grade overperformance: Silver head grade averaged 481 grams per tonne during the quarter, contributing to a year-to-date average of 485g/t. This continues to outperform expectations and underscores the high-grade nature of the Juanicipio deposit. Improved metal recovery: Metal recovery rates continue to improve, highlighting the success of ongoing operational enhancements and circuit optimizations at the Juanicipio plant. Robust production: Juanicipio achieved strong preliminary production estimates of 4.9 million silver ounces and 10,801 gold ounces, exceeding quarterly expectations and demonstrating the strength of the asset. Guidance on-track: With continued operational outperformance, silver grades are expected to be at the top end of revised guidance (420g/t to 460g/t) for 2024, reinforcing confidence in Juanicipio's long-term potential. Comprehensive financial and operational results are expected to be released on November 8.
|
LII | Hot Stocks06:48 EDT Lennox Chief Legal Officer John Torres to retire, Monica Brown to succeed - Lennox announced that executive VP, Chief Legal Officer and Secretary John Torres has elected to retire effective February 28, 2025, after 16 years with the company. Monica Brown, VP and deputy general counsel, will succeed Torres as executive VP, chief legal officer and secretary effective January 1, 2025. Torres's continued availability through February 2025 will ensure a leadership transition.
|
ITI | Hot Stocks06:45 EDT Iteris' stockholders approve merger agreement with Almaviva - Iteris announced that Iteris stockholders approved the proposed merger agreement with Almaviva at Iteris' Special Meeting of Stockholders held yesterday. As previously announced, under the terms of the merger agreement, Almaviva will acquire Iteris in an all-cash transaction in which Iteris' stockholders will receive $7.20 per share of common stock, valuing Iteris at approximately $335M equity value. The parties anticipate the transaction will close on or about November 1, subject to customary closing conditions. Upon completion of the merger, Iteris common stock will no longer be listed on any public market. More than 98% of the shares of Iteris common stock present, in person or by proxy, at the Special Meeting representing approximately 71% of Iteris' total issued and outstanding shares of common stock as of the record date, voted in favor of the merger agreement and transaction.
|
LYG | Hot Stocks06:40 EDT Lloyds Banking reaffirms 2024 guidance - The company said, "Based on our current macroeconomic assumptions, for 2024 the Group continues to expect: Banking net interest margin of greater than 290 basis points; Operating costs of c.GBP 9.4 billion, including the c.GBP 0.1 billion Bank of England Levy; Asset quality ratio to be less than 20 basis points; Return on tangible equity of c.13 per cent; Capital generation of c.175 basis points; Risk-weighted assets between GBP 220 billion and GBP 225 billion; To pay down to a CET1 ratio of c.13.5 per cent."
|
WAB | Hot Stocks06:32 EDT Wabtec sees FY24 operating cash flow conversion of greater than 90%
|
GEV | Hot Stocks06:29 EDT GE Vernova reaffirms 2024 financial guidance
|
GEV | Hot Stocks06:29 EDT GE Vernova: Experienced one fatality in Q3 - Says remains committed to fatality-free operations and deploying Life Saving Rules.
|
MCD | Hot Stocks06:28 EDT McDonald's links E. Coli to onions, pulls Quarter Pounder in affected areas - McDonald's said last night in a statement: "Across the McDonald's System, serving customers safely in every single restaurant, each and every day, is our top priority and something we'll never compromise on. It is why we are taking swift and decisive action following an E. Coli outbreak in certain states. The initial findings from the investigation indicate that a subset of illnesses may be linked to slivered onions used in the Quarter Pounder and sourced by a single supplier that serves three distribution centers. As a result, and in line with our safety protocols, all local restaurants have been instructed to remove this product from their supply and we have paused the distribution of all slivered onions in the impacted area Out of an abundance of caution, we are also temporarily removing the Quarter Pounder from restaurants in the impacted area, including Colorado, Kansas, Utah and Wyoming, as well as portions of Idaho, Iowa, Missouri, Montana, Nebraska, Nevada, New Mexico, and Oklahoma. We take food safety extremely seriously and it's the right thing to do. Impacted restaurants are receiving a stock recovery notice today and should reach out to their field supply chain manager or distribution center with any questions. We are working in close partnership with our suppliers to replenish supply for the Quarter Pounder in the coming weeks (timing will vary by local market)." Reference Link
|
TMHC | Hot Stocks06:28 EDT Taylor Morrison sees FY24 home closings 12,725 - Sees FY24 average closing price $600,000. Sees FY24 ending active community count 330-340. Sees FY24 effective tax rate 24.5%-25%.
|
TMHC | Hot Stocks06:26 EDT Taylor Morrison sees Q4 home closings 3,400 - Sees Q4 average closing price $610,000. Sees Q4 ending active community count 330-340. Sees Q4 effective tax rate 25%
|
DB | Hot Stocks06:24 EDT Deutsche Bank seeks ECB authorization for further share repurchases - The Common Equity Tier 1 capital ratio was 13.8% in the quarter, up from 13.5% in the previous quarter. This development reflected strong third-quarter earnings and the bank's adoption of transitional rules for unrealized gains and losses of certain debt instruments. These positive impacts more than offset higher risk weighted assets, predominantly higher market risk and credit risk RWA, net of reductions from the aforementioned capital efficiency measures as part of the accelerated execution of the Global Hausbank strategy. Deutsche Bank recently sought ECB authorization for further share repurchases.
|
DB | Hot Stocks06:23 EDT Deutsche Bank sees further reduction in provision for credit losses in future - Provision for credit losses was EUR 494M in the quarter, up from EUR 245M in the prior year quarter and up slightly from EUR 476M in the second quarter of 2024. Provisions for performing loans were EUR 12M, down from EUR 35M in the previous quarter. This reflected softer macro-economic forecasts and the recalibration of overlays, partially offset by portfolio movements since the second quarter. Provision for non-performing loans were EUR 482M, up from EUR 441M in the previous quarter. The quarter-on-quarter increase was driven predominantly by the Private Bank and included residual effects from remaining impacts from Postbank integration which are expected to normalize in the coming quarters, while overall portfolio quality remained largely stable. Provisions relating to commercial real estate were down 34% compared to the previous quarter and included provisions relating to expected sales in the fourth quarter. For the first nine months, provision for credit losses was EUR 1.4B, up from EUR 1B year on year. This development was substantially driven by certain larger corporate events, for which provisions are partly mitigated by offsetting hedges; residual impacts from the Postbank integration which are expected to decrease significantly going forward; and higher provisions in commercial real estate compared to the first nine months of 2023. The bank sees signs of stabilization in commercial real estate and expects this to support a further reduction in provisions in future quarters.
|
RVMD | Hot Stocks06:17 EDT Revolution Medicines presents data from RMC-6236 Monotherapy Study - Revolution Medicines announced encouraging antitumor activity and safety/tolerability data for RMC-6236, its RAS multi-selective inhibitor, in patients with previously treated pancreatic ductal adenocarcinoma, or PDAC. These updated results were presented during a late-breaking poster session at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, October 23-25. The RMC-6236-001 Phase 1/1b study is a multicenter, open-label, dose-escalation and dose-expansion study designed to evaluate RMC-6236 as monotherapy in patients with advanced solid tumors harboring RAS mutations or wild-type RAS. As of the July 23, 2024 data cutoff date, a total of 127 patients previously treated for PDAC were treated with RMC-6236 at doses ranging from 160 mg to 300 mg once daily. RMC-6236 appeared to be generally well tolerated at dose levels ranging from 160 mg to 300 mg QD and showed an overall safety profile consistent with previously reported results. No new safety signals were observed. The most common treatment-related adverse events, or TRAEs, were rash and GI-related toxicities that were primarily Grade 1 or 2 in severity. The most common reported Grade greater than or equal to3 TRAEs were rash, stomatitis, and diarrhea. TRAEs leading to dose modification occurred in 35% of patients with no treatment discontinuations due to TRAE. The average dose intensity across doses ranging from 160 mg to 300 mg was 92%.
|
AAL | Hot Stocks06:16 EDT American Airlines fined $50M for treatment of passengers with disabilities - The U.S. Department of Transportation announced a $50M penalty against American Airlines for numerous serious violations of the laws protecting airline passengers with disabilities between 2019 and 2023. DOT's investigation into American Airlines uncovered cases of unsafe physical assistance that at times resulted in injuries and undignified treatment of wheelchair users, in addition to repeated failures to provide prompt wheelchair assistance. American also mishandled thousands of wheelchairs by damaging them or delaying their return, leaving travelers without the device they need for mobility. "The era of tolerating poor treatment of airline passengers with disabilities is over," said U.S. Transportation Secretary Pete Buttigieg. "With this penalty, we are setting a new standard of accountability for airlines that violate the civil rights of passengers with disabilities. By setting penalties at levels beyond a mere cost of doing business for airlines, we're aiming to change how the industry behaves and prevent these kinds of abuses from happening in the first place." As part of the $50M penalty, American Airlines will be required to pay a $25M fine to the U.S. Treasury. In addition, American Airlines will be credited $25M towards the total penalty for investments in equipment to reduce incidents of wheelchair damage, investments in a systemwide wheelchair tagging system to reduce incidents of wheelchair delay, deployment of hub control center employees to coordinate wheelchair handling on a systemwide basis at large airports, and compensation for affected passengers during the timeframe covered by DOT's investigation. If these expenditures are not made, the additional $25M will be paid as a fine to the U.S. Treasury. Reference Link
|
DB | Hot Stocks06:15 EDT Deutsche Bank 'made progress on all dimensions' of Global Hausbank strategy - Deutsche Bank made progress on all dimensions of its accelerated Global Hausbank strategy in the third quarter: Revenue growth: Revenues grew 5% year on year to EUR 7.5B in the quarter, with 5% growth in commissions and fee income, as net interest income in the key segments of the banking book was broadly stable year on year. The bank's compound annual revenue growth rate over the last 12 months compared with the full year 2021 was 5.6% at the end of the quarter, within the bank's raised target range of between 5.5% and 6.5%. Operational efficiency: The bank made further progress on its EUR 2.5B Operational Efficiency program which includes optimization of the platform in Germany and workforce reductions, notably in non-client-facing roles. In the third quarter, total savings either realized or expected from measures completed reached EUR 1.7B, including EUR 1.5B in savings realized. Workforce reductions related to the program reached a cumulative total of approximately 3,300 full-time equivalents, including approximately 600 during the third quarter, more than 90% of the planned total through year end 2024. In addition, contract external staff have been reduced by approximately 1,400, notably through internalisations, in the first nine months of 2024. Capital efficiency: Deutsche Bank delivered RWA equivalent benefits of a further EUR 3B during the third quarter through data and process improvements. As a result, cumulative RWA reductions from capital efficiency measures reached EUR 22B, marking further progress towards the bank's raised goal of EUR 25-30B by the end of 2025. Deutsche Bank continues to pursue additional opportunities to exceed this goal.
|
RPTX | Hot Stocks06:12 EDT Repare Therapeutics presents data from Phase 1 MYTHIC clinical trial - Repare Therapeutics presented updated data highlighting the benefits of its individualized schedule for the management of anemia in the Phase 1 MYTHIC clinical trial treating patients with the combination of lunresertib, a first-in-class PKMYT1 inhibitor, and camonsertib, a potential best-in-class oral small molecule ATR inhibitor. Lunre+camo in the MYTHIC clinical trial previously demonstrated promising clinical activity in molecularly selected patients across multiple tumor types. In this analysis, Repare followed patients for approximately nine months at the recommended Phase 2 dose to assess the effectiveness of an individualized schedule. The analysis demonstrated a successful approach to mitigating mechanism-based anemia while maintaining clinical benefit. Further, Repare observed no thrombocytopenia of any grade nor serious neutropenia in these patients. Dr. Martin Hojgaard of Rigshospitalet, Denmark presented this data in a poster titled, "Individualized schedule improves rates and severity of anemia in patients treated with lunresertib, a PKMYT1 inhibitor, and camonsertib, an ATR inhibitor, in the Phase I MYTHIC study" at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024 in Barcelona, Spain. "This individualized schedule in heavily pretreated patients with advanced cancers from our MYTHIC clinical trial met its goal of maintaining antitumor activity while reducing rates of grade 3 anemia," said Maria Koehler, MD, PhD, Executive Vice President and Chief Medical Officer of Repare. "We believe that these data demonstrate a favorable and differentiated tolerability profile versus both current and emerging therapies. We look forward to sharing efficacy data from the gynecological cancer expansion cohort of the MYTHIC clinical trial in December 2024."
|
BYON | Hot Stocks06:11 EDT Beyond to cut workforce by 20%, terminates Chief Product Officer - In a regulatory filing, Beyond announced that on October 20, the board of directors of the company approved a RIF affecting approximately 20% of the company's workforce, which is expected to be substantially implemented in the fourth quarter of 2024. These actions were taken to strategically create a more variable, leverageable cost structure and create a more streamlined organization to align to its asset-light business that supports an affinity and data monetization model with a strong technology focus. The company estimates the RIF will result in annualized reduction of fixed costs by approximately $20M. In connection with a reduction in force, Carlisha Robinson, former Chief Product Officer of Beyond, was terminated without cause effective October 22.
|
SDGR | Hot Stocks06:09 EDT Schrodinger presents SGR-3515 preclinical data at ENA 2024 - Schrodinger announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR Symposium. The data demonstrate that in preclinical models, treatment with SGR-3515 results in synergistic anti-tumor activity that leads to deeper and more durable responses compared to inhibitors that target only Wee1 or Myt1. The preclinical data also show that SGR-3515 has a favorable pharmacological profile and dosing schedule that supports evaluating intermittent dosing in patients. Wee1 and Myt1 kinases regulate the cell cycle and DNA damage response, allowing time for DNA repair before cell division takes place. Concurrent loss of function or inhibition of Wee1 and Myt1 confers selective vulnerability in cancer cells, a mechanism referred to as synthetic lethality, which has become an emerging therapeutic strategy for a range of cancers. A Phase 1 dose-escalation study of SGR-3515 in patients with advanced solid tumors is ongoing in the U.S. and Canada, and initial data from the clinical study is expected in the second half of 2025. Schrodinger will also present preclinical data from its PRMT5-MTA program during a poster session on October 25. Schrodinger scientists have identified a novel series of selective, potent PRMT5-MTA inhibitors and are optimizing lead compounds for use in peripheral and brain tumors.
|
TPC | Hot Stocks06:07 EDT Tutor Perini unit awarded $1.1B Kensico-Eastview Connection Tunnel Project - Tutor Perini announced that its subsidiary, Frontier-Kemper Constructors has been awarded a contract valued at approximately $1.1B by the New York City Department of Environmental Protection for the Kensico-Eastview Connection Tunnel Project. The scope of work entails the construction of a new deep rock tunnel between the Kensico Reservoir and the Catskill/Delaware Ultraviolet Light Disinfection Facility, both in Westchester County, New York. The new tunnel will provide an additional means of conveying water between the Kensico Reservoir and the CDUV Facility, enhancing operational resiliency and redundancy for New York City's water supply system. Work is expected to begin in the coming months with substantial completion expected in 2030. The contract value was added to the company's backlog in the third quarter of 2024.
|
VIOT | Hot Stocks06:05 EDT Viomi Technology extends share repurchase plan for 12 months - Viomi Technology announced that as part of the company's continuous commitment to enhancing shareholder value, its board of directors has approved an extension of its existing share repurchase plan for an additional 12 months. Under this extended share repurchase plan, the company may repurchase up to $10M worth of its ADSs between October 25, 2022, and October 24, 2025. To date, the company has purchased an aggregate of $901,258 worth of its ADSs in the open market.
|
AMZN | Hot Stocks06:04 EDT Amazon.com announces new fuel savings offer for Prime Members - Amazon announced that Prime members can now save 10c per gallon at approximately 7,000 bp, Amoco, and ampm gas stations across the U.S. This offer could save Prime members on average nearly $70 per year on gas if purchasing at qualifying locations. Additionally, Prime members can expect even more savings on transportation-related costs in the future-in 2025, Amazon plans to add an electric vehicle charging savings offer with bp pulse, bp's electric vehicle charging business, with more details to be revealed next year.
|
QCOM... | Hot Stocks05:59 EDT Qualcomm announces collaboration with Google for generative AI cockpit solutions - Qualcomm (QCOM) on Tuesday announced a multi-year technology collaboration with Google (GOOGL) aimed at advancing digital transformation in automotive. Building on a long-standing relationship, the companies will leverage technologies from the Snapdragon Digital Chassis, Android Automotive OS and Google Cloud to produce a new standardized reference platform for the development of cockpit solutions using generative artificial intelligence. Underpinning the delivery of this framework will be Google AI, to create Gen AI-enabled in-car experiences like intuitive voice assistants, immersive map experiences, and real-time updates to anticipate driver needs, powered by Snapdragon heterogeneous edge AI system-on-chips and Qualcomm AI Hub. "Our technology collaboration with Google to drive innovation and develop cutting-edge, Gen AI-enabled solutions is a significant milestone in unlocking new possibilities for automakers and Tier-1 suppliers while empowering the industry to create safe and digitally advanced experiences," said Nakul Duggal, group general manager, automotive, industrial and cloud, Qualcomm Technologies, Inc. "We look forward to extending our work with Google to further advance automotive innovation and lead the go-to-market efforts leveraging our ecosystem of partners to enable a seamless development experience for our customers." Reference Link
|
BERY GLT | Hot Stocks05:35 EDT Berry Global, Glatfelter provide update on HHNF spin-off and merger completion - Berry Global (BERY) and Glatfelter (GLT) announced that Berry has set a record date of the close of business on November 1 for the proposed spin-off of its Health, Hygiene and Specialties Global Nonwovens and Films business, or HHNF Business. The spin-off and merger of Berry's HHNF Business with Glatfelter are expected to be completed on November 4, subject to the satisfaction or waiver of the closing conditions for the transaction. As previously announced, in connection with the merger, Glatfelter will effect a reverse stock split and change its name to Magnera Corporation. Subject to the satisfaction or waiver of the closing conditions, on November 4, Berry will distribute all of the shares of stock of its wholly owned subsidiary that owns the HHNF Business to Berry stockholders as of the close of business on the November 1 record date by means of a pro rata distribution, Spinco will merge into a subsidiary of Magnera, and the shares of Spinco distributed to Berry stockholders will convert into the right to receive Magnera shares. Upon completion of the merger, Berry stockholders are expected to collectively own approximately 90% of the outstanding shares of Magnera common stock on a fully-diluted basis, and current Glatfelter shareholders are expected to collectively own approximately 10% of the outstanding shares of Magnera common stock on a fully-diluted basis. The actual number of shares of Magnera common stock that Berry stockholders will receive in the spin-off and merger with respect to each share of common stock, $0.01 par value per share of Berry will be determined based on the number of shares of Glatfelter common stock outstanding on a fully-diluted basis prior to the merger, the number of shares of Spinco common stock outstanding, which will equal the number of shares of Berry common stock outstanding on the actual record date, and the reverse stock split ratio determined by Glatfelter's board of directors. The spin-off and merger remain subject to the satisfaction or waiver of certain conditions including, but not limited to, approval by Glatfelter shareholders of certain matters related to the transactions. If the closing conditions are not satisfied or waived in advance of November 1, Berry may elect to change the record date to a later date.
|
SYNA | Hot Stocks05:29 EDT Synaptics expands in Taiwan - Synaptics announced it has expanded in Hsinchu, now making Taiwan Synaptics' largest employee base worldwide. The expansion underscores the increasingly large role of Taiwan in the semiconductor industry and gives Synaptics headroom to grow both its essential operations and engineering expertise. Among other things, the facilities will house the team that develops AI-enabled Edge devices for the IoT to capture a piece of the rapidly growing $24B market across consumer, automotive, enterprise, and industrial applications.
|
LRE MRM | Hot Stocks05:28 EDT Lead Real Estate to introduce Mother Bracelet fitness trackers to two hotels - Lead Real Estate (LRE) announced that LRE will introduce Mother Bracelet, a fitness tracker developed by Medirom Mother Labs, a subsidiary of Medirom Healthcare (MRM), which operates a health tech business, to two hotels under the ENT Terrace brand. This initiative will launch on Friday, November 1, under the theme "Circulation of Happiness through Energy of Travel." Mother Bracelet is a fitness tracker that does not require charging. Following the introduction, these trackers will be available free of charge to guests staying at the ENT Terrace hotels. In addition to visualizing their own health condition, guests can earn energy points just by walking.
|
EVO BMY | Hot Stocks05:16 EDT Evotec and Bristol Myers expand proteomics pact, triggers $50M payment - Evotec (EVO) announced progress within the company's strategic partnership with Bristol Myers Squibb (BMY) relating to building a molecular glue-based pipeline. Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology, triggering a program-based payment of $50M to Evotec. Based on potential program-based milestones, the expansion contributes to the deal value. Evotec and Bristol Myers Squibb entered their strategic protein degradation partnership in 2018 and expanded it in May of 2022, because of the initial collaboration generating a promising pipeline. Since the expansion, Evotec has scaled up its activities to develop compounds from Bristol Myers Squibb's library of cereblon E3 ligase modulators.
|
LLY | Hot Stocks05:08 EDT Eli Lilly announces MHRA grants marketing authorization for donanemab - Eli Lilly announced that the Medicines and Healthcare products Regulatory Agency, or MHRA, has granted marketing authorization for donanemab, an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer's disease in eligible adults in Great Britain. Eligible patients are limited to apolipoprotein E e4, or ApoE e4, heterozygotes or non-carriers, which is a requirement for the class of currently approved amyloid-targeting therapies in Great Britain. Donanemab is the only amyloid plaque-targeting therapy with evidence to support stopping therapy when amyloid plaques are removed. Great Britain is the third major market to approve donanemab, marketed as Kisunla.
|